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Abstract 
Of the minimal information describing drug dialyzability, the majority was obtained prior to 
modern hemodialysis membranes. This study characterized the dialyzability of the most 
commonly prescribed beta blockers in patients undergoing high-flux hemodialysis. Eight 
subjects were recruited to a pharmacokinetic, 4-way crossover trial. Drug concentrations 
were measured using mass spectrometry and dialyzability determined by the arterial-venous 
difference and recovery clearance methods. A provincial-wide retrospective cohort study was 
designed to determine the effect of dialyzability on adverse clinical outcomes. Beta blocker 
efficacy can be hindered if substantial clearance occurs during dialysis. Our results 
demonstrate atenolol and metoprolol are extensively cleared during hemodialysis, while 
carvedilol displays low dialyzability. Although bisoprolol was previously considered to be 
minimally dialyzed, we now demonstrate moderate dialyzability. This highlights the 
importance of conducting dialyzability studies. With recent findings suggesting heightened 
mortality risk in hemodialysis patients prescribed highly dialyzed beta blockers, dialyzability 
data is critical to optimize pharmacotherapy.  
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1.1 Renal Physiology 
Our understanding of renal physiology continues to advance at an accelerated 
rate, especially due to global trends of a growing renal impairment population. Yet, the 
basic lessons learned from early measurements and elegant studies still provide the 
foundation for researchers today. The overarching role of the kidneys to maintain 
physiological homeostasis is now empirically recognized. Despite only weighing 150 
grams each, kidneys receive more than 20% of the cardiac output supplied by the heart 
(Suzuki and Saruta, 2004). This highlights the responsibility of the kidneys to filter blood 
and remove excess organic molecules, regulate electrolyte balance, and maintain body 
fluid volume. All these functions are interrelated to the crucial role of the renal system in 
regulating long-term systemic blood pressure (Suzuki and Saruta, 2004).  
 The renin-angiotensin aldosterone system (RAAS) utilizes a negative feedback 
pathway to control hormone production, which subsequently modulates blood pressure 
(Gross et al., 1964). In short, insufficient levels of sodium in circulation can be sensed by 
macula densa cells of the kidneys and lead to the production of renin by juxtaglomerular 
cells. Angiotensinogen—a plasma protein constitutively produced by the liver—is 
converted into angiotensin I by renin which serves as the rate limiting enzymatic step in 
RAAS. Upon reaching the lungs, angiotensin I is further transformed into angiotensin II 
by angiotensin-converting enzyme (ACE). Angiotensin II is a potent vaso-active 
hormone that raises blood pressure through direct widespread vasoconstriction. This 
hormone can also indirectly regulate blood pressure by altering sodium reabsorption and 
promoting aldosterone secretion. Aldosterone itself can lead to further increase in blood 
pressure by means of water and sodium retention. It comes as no surprise that 
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inappropriate activation of RAAS is recognized as one of the main mechanisms for 
hypertension progression (Campese and Park, 2006). Hence, many pharmacological 
compounds developed in the last 40 years have utilized this homeostatic system to 
combat hypertension and cardiovascular disease. ACE inhibitors and angiotensin receptor 
blockers (ARBs) have now become first-line treatments for many patients today, 
including those with renal impairment (Becker et al., 2012). 
 
1.2 Overview of Chronic Kidney Disease  
1.2.1 Prevalence, Detection, and Progression 
Similar to other economically developed nations, Canada is defined by its ageing 
population. Such a characterization has profound implications on the health care system, 
requiring greater emphasis on optimizing treatment for chronic diseases (Wiener and 
Tilly, 2002; Lefebvre and Goomar, 2005). In particular, chronic kidney disease (CKD) 
has quickly developed into one of the largest national health concerns in recent times.  
Approximately 12.5% of adults in Canada are living with some form of CKD, which is 
similarly observed in the USA’s population (13.1%) (Coresh et al., 2007; Arora et al., 
2013). Focusing specifically on patients over the age of 60, the prevalence of CKD is 
markedly higher with estimates surpassing 30% in Canada and the USA (Arora et al., 
2013; Saran et al., 2016). In both these nations, CKD affects a greater proportion of the 
population as compared to Europe (4.7–8.1 %), Asia (2.5–6.8 %) and Australia (11.2%) 
(Zhang and Rothenbacher, 2008). These statistics emphasize the importance of early 
disease recognition in hopes of preventing CKD progression in North America. 
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CKD is an irreversible condition that is typically characterized by three or more 
months of renal abnormalities leading to a progressive decline in estimated glomerular 
filtration rate (eGFR) (Stevens et al., 2013). With a lower GFR, serum urea and 
creatinine levels in CKD patients begin to elevate and serve as estimates of renal function 
(Smith et al., 2006). Outlined by the severity in kidney dysfunction and classified based 
on eGFR measurements, patients advance through five successive stages of CKD.  The 
most commonly used method to assess patient eGFR is the Modification of Diet in Renal 
Disease (MDRD) Study equation, which takes into consideration serum creatinine, age, 
gender and ethnicity of patients (Levey et al., 1999). However, for patients who exhibit 
an actual measured GFR value greater than 60 mL/min/1.73 m2, this equation often leads 
to an over diagnosis of CKD severity due to its frequent underestimation of eGFR 
(Stevens et al., 2007). Consequently, the National Kidney Foundation has recommended 
the use of the CKD-EPI method to assess kidney function based on its improved accuracy 
to correctly categorize patients into their appropriate stage of CKD (Stevens et al., 2010; 
Stevens et al., 2011). This estimating equation considers the same variables as the 
MDRD method and defines normal kidney function as having an eGFR of at least 90 
mL/min/1.73m2 with no albuminuria or structural abnormalities (KDIGO CKD Work 
Group, 2013). Since minimal decline in GFR is observed for patients in early stages of 
CKD, the albumin to creatinine ratio (ACR) is analyzed in urine samples to assess and 
diagnose any initial deterioration in renal function. Albumin detection in urine suggests 
increased glomerular permeability as a result of kidney injury. Patients are categorized 
into one of the three classifications of ACR: normal (< 30 mg/g creatinine), moderately 
increased (30–300 mg/g creatinine) or severely increased (> 300 mg/g creatinine). In 
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clinical practice, combining both eGFR and ACR allows physicians to determine an 
individual’s risk for CKD progression (Table 1.1).  
Patients with CKD stage 1 or 2 exhibit normal (≥ 90 mL/min/1.73 m2) or 
marginally decreased (60–89 mL/min/1.73 m2) eGFR with abnormalities in kidney 
function observed through elevated ACR. Patients with stage 3 CKD (eGFR of 30–59 
mL/min/1.73 m2) account for more than half of the patient population (Coresh et al., 
2007). During this stage, accumulation of uremic toxins as a consequence of hindered 
renal clearance causes the development of uremic syndrome and other comorbidities. The 
condition of uremia causes physiological changes that affect cognitive function, alter 
basal metabolic rate, disturb hormonal regulation, and lead to overall imbalances in 
homeostasis (Depner, 2001; Meyer and Hostetter, 2007). As a result, a substantial 
increase in risk of death, cardiovascular events and hospitalizations is observed for stage 
3 CKD patients with an eGFR of less than 45 mL/min/1.73 m2 (Go et al., 2004). For 
some patients, continued decline of eGFR and renal function will ultimately lead to stage 
5 CKD (eGFR < 15 mL/min/1.73 m2), also known as end-stage renal disease (ESRD). If 
left untreated, the severity of comorbidities and complications amongst ESRD patients 
result in a nearly 600 percent increase in risk of mortality as compared to CKD patients in 
stage 1 or 2 (Go et al., 2004). Although preventing disease progression is an important 
aspect of managing renal insufficiency, more effective treatment plans to address 
comorbidities and complications are needed to improve the prognosis of CKD patients. 
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Table 1.1. Grid of eGFR and albuminuria levels reflecting risk for CKD progression by intensity 
of colouring (green, yellow, orange and red). 
 
Albuminuria Categories 
Normal 
Moderately 
Increased 
Severely 
Increased 
 
CKD 
Stage 
eGFR Description 
ACR < 30 mg/g 
creatinine 
ACR 30–300 
mg/g creatinine 
ACR > 300 
mg/g creatinine 
eG
F
R
 C
at
eg
o
ri
es
 (
m
L
/m
in
/1
.7
3
m
2
) 
1 ≥ 90 Normal 
Low Risk Moderate Risk High Risk 
2 60–89 Mild ↓GFR 
3 30–59 
Moderate 
↓GFR 
High Risk  
4 15–29 
Severe 
↓GFR 
                        Very High Risk 
 
 
 5 <15 
Kidney 
Failure 
Adapted from KDIGO, 2013.  
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1.3 Causes and Complications in Chronic Kidney Disease 
1.3.1 Diabetes in CKD 
Diabetes mellitus (henceforth referred to as diabetes) is the primary cause of CKD 
and accounts for 36% of ESRD patients in Canada (Canadian Institute for Health 
Information, 2016). With trends suggesting a continued growth in the global burden of 
diabetes and nearly 5 million Canadians projected to be diagnosed with the condition by 
2025, the proportion of CKD attributable to diabetes will inevitably rise (Guariguata et 
al., 2014; Canadian Diabetes Association, 2015). Accordingly, healthcare professionals 
can attempt to delay CKD progression by ensuring early detection and creating 
appropriate treatment plans for diabetic patients. In type 2 diabetes, 39% of patients 
demonstrate microalbuminuria (ACR of 30–300mg/g creatinine) and 10% are diagnosed 
with macroalbuminuria (ACR greater than 300 mg/g creatinine)—both of which are 
powerful risk factors for diabetic nephropathy and cardiovascular disease (Ljungman et 
al., 1996; Parving et al., 2006; Chronic Kidney Disease Prognosis Consortium et al., 
2010). An additional measure to ascertain diabetes severity is the level of glycated 
hemoglobin (HbA1c) found in patient blood, which estimates the average plasma glucose 
concentration over the previous three months. Hyperglycemia is the most notable feature 
of diabetes and the underlying determinant for vascular target organ conditions, including 
diabetic kidney disease. High blood glucose can lead to damage of renal capillaries 
causing hyperfiltration by the glomerulus and subsequent microalbuminuria (Kanwar et 
al., 2008). Hence, the National Kidney Foundation has recommended intensive glycemic 
control in CKD patients by suggesting a target HbA1c of 7% to reduce albuminuria 
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progression (KDOQI, 2007). Any further reduction in the target levels of HbA1c should 
be avoided due to significantly heightened risks for severe hypoglycemia and all-cause 
mortality (Ismail-Beigi et al., 2010; Shurraw et al., 2011). 
In an effort to manage their blood glucose levels, diabetic patients are often 
prescribed oral antihyperglycemic agents with or without insulin. Unfortunately, 
difficulty in maintaining appropriate glycemic control in CKD patients arises as a result 
of dosing adjustments required for many medications. For instance, metformin is a first-
line medication for the treatment of type 2 diabetes. The use of metformin in patients 
with CKD stage 3 or higher is often avoided due to a heightened risk for adverse drug 
effects, including lactic acidosis (Lalau et al., 2015). Further complicating glycemic 
management is the development of insulin resistance, and hindered insulin secretion and 
clearance in CKD patients (Williams and Garg, 2014). Devising appropriate strategies to 
optimize the management of hyperglycemia slows the progression of CKD, decreases 
cardiovascular risk, and improves overall patient prognosis (The Diabetes Control Group, 
1993; The Diabetes Control Group, 1995; Ray et al., 2009).  
1.3.2 Cardiovascular Disease in CKD 
Hypertension is the most common comorbidity experienced by CKD patients with 
a prevalence estimate of up to 75% for those with eGFR less than 60 mL/min/1.73m2 
(stages 3-5) (National Kidney Foundation, 2002). Not surprisingly, renal vascular disease 
is a main cause for many of the adverse outcomes observed in CKD, including renal 
failure, early development and augmented progression of cardiovascular disease, and 
premature mortality (Levey et al., 1998). With a growing awareness that renal 
impairment patients are more likely to die from an adverse cardiac event than progress to 
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ESRD (Keith et al., 2004), all CKD patients are now regarded as the highest risk group 
for cardiovascular disease, irrespective of any risk factors (National Kidney Foundation, 
2002). The complicated interaction between CKD and cardiovascular disease can be 
attributed to the increased risk for both traditional (hypertension, advanced age, diabetes, 
and hyperlipidemia) and CKD-specific risk factors (inflammation, malnutrition, mineral 
disorders, and anemia). The aggregate of all such risk factors has resulted in a nearly 70% 
prevalence estimate of cardiovascular disease among elderly CKD patients—two-fold 
greater than what is observed in the general elderly population (Saran et al., 2016).   
Congestive heart failure and atherosclerotic heart disease are the two primary 
clinical presentations of cardiovascular comorbidity in the CKD population (Saran et al., 
2016). Acceleration in atherosclerotic plaque development has been an evident problem 
for hemodialysis patients for over 30 years (Lindner et al., 1974). The asymptomatic 
nature of coronary artery disease combined with increased inflammation and oxidative 
stress in CKD has created a challenging circumstance for preventing atherosclerosis 
progression (deFilippi et al., 2003; Ohtake et al., 2005). Correspondingly, recognition 
that vascular calcification is very common amongst CKD patients supports the finding of 
a heightened risk for heart failure in this population (Chertow et al., 2002; Moe et al., 
2002). In a large population-based study conducted in the USA, the rate of cardiac failure 
in stage 3-5 CKD patients was 3-fold higher as compared with non-CKD subjects 
(Kottgen et al., 2007). ESRD patients diagnosed with heart failure at the start of their 
renal replacement therapy (RRT) are strongly associated with short and long-term 
mortality. Specifically, the median survival time of dialysis patients diagnosed with 
baseline heart failure is 36 months, whereas dialysis patients without heart failure has an 
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estimated survival of 62 months (Harnett et al., 1995). Although significant 
improvements have been made for the management of cardiovascular disease in the 
general population, many of the interventions either lack clinical investigation in patients 
receiving RRT or have been shown to be less effective. For instance, the lipid-lowering 
class of medications known as statins are the best-selling drugs in history due to their 
proven efficacy to reduce cardiovascular disease and mortality (Scandinavian Simvastatin 
Survival Study Group, 1994; Nawrocki et al., 1995; World Health Organization, 2004; 
Epidemiological Studies Unit, 2005). However, three large randomized, placebo-
controlled trials studying the use of statins in dialysis patients did not display any survival 
benefit (Fellström et al., 2009). These findings have ultimately warranted updates to 
clinical practice guidelines recommending statin therapy should no longer be initiated for 
dialysis-dependent CKD (Wanner et al., 2005; Baigent et al., 2011; Tonelli et al., 2014). 
More prospective trials are required to compare and determine which medications 
provide the best cardiovascular protection in subjects treated with RRT.  
 
1.4 Renal Replacement Therapy for End-Stage Renal 
Disease 
As kidney function and eGFR continue to decline for CKD patients, those who 
reach stage 5 will require RRT to prolong survival. A recent report drawing on data from 
the Canadian Organ Replacement Register (CORR) has shown that the prevalence of 
ESRD patients being treated with some form of RRT has increased over two and half fold 
from 13,230 patients in 1995 to 35,281 in 2014 (Canadian Institute for Health 
Information, 2016). Clinical decisions for the modality and time of RRT initiation still 
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remain controversial. Treatment regimen can be divided into patients of “early-start” or 
“late-start” dialysis (Cooper et al., 2010). In early-start, patients are educated and 
prepared for RRT during stage 4 CKD to ensure immediate commencement of dialysis 
once stage 5 CKD is reached. In comparison, late-start dialysis is initiated when patient 
eGFR falls below 15 mL/min/m2 and begin to experience signs and symptoms of uremia 
including cognitive decline, fluid overload, electrolyte imbalances, and hormonal 
disturbances (Depner, 2001). Results from the IDEAL (Initiating Dialysis Early And 
Late) study—a randomized, controlled trial comparing time of dialysis initiation—has 
since prompted the National Kidney Foundation to update their guidelines in favour of 
commencing dialysis once uremic symptoms become apparent (National Kidney 
Foundation, 2015). However, healthcare professionals and patients must still work 
together to select an extracorporeal (hemodialysis) or paracorporeal (peritoneal dialysis) 
method of dialysis, and whether it will be administered continuously or intermittently. 
1.4.1 Hemodialysis 
Intermittent, institutional hemodialysis is the most frequently elected form of 
RRT and has consistently represented 77% of all new dialysis patients in Canada over the 
past decade (Canadian Institute for Health Information, 2016). This mode of RRT is 
usually administered thrice weekly for 3-4 hours per session. A vascular access location 
must first be surgically created to allow withdrawal of arterial blood from patients into 
the hemodialysis machine. Regarding the choice of vascular access, 80% of patients 
utilize a central catheter despite numerous functional advantages of fistulas (Moist et al., 
2014). Specifically, fistulas have lower rates of thrombosis and infections, require fewer 
interventions, and provide greater longevity in vascular access (Nassar and Ayus, 2001; 
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Huber et al., 2003; Perera et al., 2004). Most importantly, patients receiving catheters had 
a nearly two and half fold greater risk for mortality as compared to patients dialyzed with 
fistulae (Dhingra et al., 2001).  
Within the dialyzer, a countercurrent flow of dialysate maintains a concentration 
gradient across the dialysis membrane and ensures the diffusion of ions, solutes, and 
excess water out of blood. Fluid removal known as ultrafiltration can also be achieved by 
varying the hydrostatic pressure of the dialysate to produce a pressure gradient. The 
filtered blood can then re-enter systemic circulation of patients through the dialysis 
venous line. Dialysate is a salt solution containing glucose and many different ions. The 
composition of dialysate is essential for ensuring patients receive effective hemodialysis 
therapy since it dictates the balance of electrolyte and mineral concentrations in blood. 
For instance, adequate sodium and water removal during dialysis is crucial in minimizing 
inter- and intra-dialytic hypertension and edema (Locatelli et al., 2015). Potassium 
homeostasis is critical for preventing cardiac arrhythmias, and bicarbonate levels stabilize 
physiological pH in order for optimal protein function.  
The physiological goals for hemodialysis can differ between patients and require 
individualized treatment regimens. Specifically, extracorporeal filtration is dependent on 
the blood and dialysate flow rate, duration and frequency of dialysis, and the composition 
of dialysis membrane including pore size, surface area and material (National Kidney 
Foundation, 2015). Older, conventional dialysis is characterized by low-flux membranes 
containing small pore sizes. Recently, there has been a widespread trend in opting for use 
of high-flux dialyzers due to their advantage of removing larger solutes and shorter 
requirements for dialysis duration (Schneider and Streicher, 1985). Whether high-flux 
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dialyzers actually improve patient outcomes still remain controversial. Three large-scale 
randomized, controlled trials demonstrated no difference in mortality between low- and 
high-flux dialyzers (Eknoyan et al., 2002; Locatelli et al., 2009; Asci et al., 2013). 
However, the National Kidney Foundation still recommends high-flux dialyzers be 
preferentially used due to improvements in secondary outcomes including cardiac 
mortality and hospitalizations (National Kidney Foundation, 2015).  
1.4.2 Peritoneal Dialysis 
In Canada, peritoneal dialysis accounts for 20% of new ESRD patients requiring 
RRT (Canadian Institute for Health Information, 2016). Being able to receive peritoneal 
dialysis treatment while at home provides a lifestyle convenience for many of these 
patients. The two main approaches for peritoneal dialysis treatment is through automated 
peritoneal dialysis (APD) or continuous ambulatory peritoneal dialysis (CAPD) 
(Fleming, 2011). Both methods of dialysis involve surgical implantation of a catheter into 
the peritoneal cavity to introduce and remove dialysate. APD is characterized by 3 to 6 
cycles of dialysate exchange overnight accomplished by a machine, followed by a small 
residual volume of dialysate during the day. Conversely, CAPD involves multiple manual 
exchanges of 2–3 litres of dialysate during the day, followed by a longer dwell time 
overnight (Fleming, 2011). The dialysate composition for either method of peritoneal 
dialysis requires a hyperosmotic solution to ensure adequate ion, solute, toxin, and water 
removal from the blood, across the peritoneum and into the dialysate. Many of the 
complications experienced by patients are due to excessive loss of fluid resulting in 
hypovolemic shock or hypotension, and increased infection rates as a consequence of the 
permanent catheter (Mehrotra et al., 2016).  
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Despite early reports from selected nephrologists suggesting that peritoneal 
dialysis is a “second-class therapy for second-class patients by second-class doctors” 
(Shaldon et al., 1985), considerable advancements in its application have resulted in 
survival benefits comparable to that of institutional hemodialysis (Yeates et al., 2012; 
Heaf and Wehberg, 2014; Marshall et al., 2015; van de Luijtgaarden et al., 2016). The 
implications of these findings not only allow patients to choose a modality of RRT that 
may be better suited for their lifestyle, but it also provides a more economically feasible 
method of dialysis to benefit the healthcare system (Karopadi et al., 2013).  
1.4.3 Kidney Transplant 
The ultimate goal for any dialysis treatment is to prolong patient survival until an 
adequate kidney transplant can be received. However, the scarce availability of organs for 
transplant restricts millions of people worldwide to long-term RRT (Fleming, 2011). In 
Canada, the number of patients waiting for a kidney transplant is steadily increasing 
every year but only 40% of those on the waitlist actually receive a kidney (Canadian 
Institute for Health Information, 2016). Despite more than 35,000 Canadians being 
treated for ESRD, the median wait time for dialysis patients to receive a kidney is 4 
years. Fortunately, living organ donation has greatly improved the outlook for renal 
transplantation over the past decade and often leads to a healthier, longer-lasting kidney 
(Davis and Delmonico, 2005).  
To date, a successful kidney allograft is the only treatment for improving GFR 
and reversing CKD. Transplant recipients no longer require dialysis therapy once their 
kidney begins to function. The risk for heart disease becomes dramatically attenuated, 
and erythropoietin synthesis commences within a matter of days allowing patients to 
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reach target levels of hemoglobin in 3 months post-surgery (Joist et al., 2006; Zolty et al., 
2008). Accordingly, the quality of life, survival, and long-term prognosis observed in 
transplant recipients are far better than ESRD patients requiring dialysis (Purnell et al., 
2013).  
 
1.5 Pharmacokinetic Studies in CKD Patients 
Emerging evidence demonstrate alterations of drug absorption, distribution, and 
non-renal elimination in renal insufficiency, providing insight as to why CKD patient 
responses to pharmacotherapy are still widely variable with frequent adverse drug events 
(Bates et al., 1999; Manley et al., 2005; Naud et al., 2012). Urea retention and its 
subsequent hydrolysis into ammonia by bacterial urease can increase intestinal pH, 
leading to changes in absorption of weakly basic drugs (Pappenheimer and Reiss, 1987; 
Velenosi and Urquhart, 2014). Upon reaching systemic circulation, attenuated production 
of albumin coinciding with competitive binding by uremic toxins result in elevated free 
fraction of medications—the outset for drug toxicity (Sakai et al., 2001). Recent 
preclinical and human studies display reductions in non-renal clearance for CKD, which 
can ultimately potentiate drug toxicity by prolonging elevated drug concentrations in 
plasma (Ahmed et al., 1991; Leblond et al., 2001; De Martin et al., 2006; Michaud et al., 
2006; Naud et al., 2008; Nolin et al., 2009; Velenosi et al., 2012; Velenosi et al., 2014; 
Thomson et al., 2015). One possible explanation for this change in drug 
pharmacokinetics is the accumulation and circulation of uremic toxins as a result of 
reduced clearance in CKD. It has been proposed that indoxyl sulfate and other uremic 
toxins can inhibit the function and expression of hepatic drug metabolizing enzymes and 
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drug transporters—both being essential contributors to drug disposition (Sun et al., 2004; 
Tsujimoto et al., 2010; Fujita et al., 2014). 
Realizing that renal impairment can substantially impact all aspects of drug 
pharmacokinetics, the FDA Clinical Pharmacology Advisory Committee proposed 
several important changes to their 1998 FDA Renal Guidance document (Huang et al., 
2009). The result of this proposal is an updated draft guidance entitled: Guidance for 
Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study Design, 
Data Analysis, and Impact on Dosing and Labeling. This draft has developed a detailed 
algorithm for deciding whether to incorporate patients with renal insufficiency in 
pharmacokinetic studies of new chemical entities (NCEs) (Huang et al., 2009). In short, 
if NCEs undergo substantial renal elimination (i.e. if at least 30% of the dose is excreted 
unchanged in urine), subjects from each stage of CKD must be included in a “full” 
pharmacokinetic study. For drugs that are primarily non-renally excreted, the new draft 
guidance recommends implementing a “reduced” study design—an important departure 
from the 1998 Renal Guidance. This design involves the comparison of drug disposition 
in healthy versus ESRD patients who have not yet been prescribed RRT. If drug exposure 
is substantially elevated in ESRD patients (e.g. an increase in the AUC of at least 50%, or 
a smaller increase for drugs with a narrow therapeutic window), a full renal study must be 
conducted. 
The importance of implementing a reduced design for drugs that may not exhibit 
renal elimination is evident for the analgesic compound, celecoxib—a selective 
cyclocooxygenase-2 (COX-2) inhibitor (Swan et al., 2000). It is well-recognized that 
prescription of conventional non-steroidal anti-inflammatory drugs (NSAIDs) are 
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accompanied by heightened risks for nephrotoxicity, especially for patients with severe 
renal insufficiency. However, celecoxib did not undergo any form of renal impairment 
study during its drug approval process as its development occurred prior to publication of 
the 1998 Renal Guidance, and its primary route of elimination is through hepatic 
metabolism. Since then, post-marketing population studies combined with data from 
FDA’s Adverse Event Reporting System has demonstrated associations of celecoxib with 
acute renal failure (Zhao et al., 2001; Ahmad et al., 2002; Schneider et al., 2006). If 
overlooked by physicians, lack of appropriate dosage adjustments for CKD patients can 
lead to an accelerated progression into kidney failure (Perazella and Eras, 2000). 
 
1.6 Drug Dialyzability 
1.6.1 Current State of Knowledge 
Drug dialyzability is defined as the efficiency of drug removal by dialysis. The 
‘Dialysis of Drugs,’ an annual publication by the renal pharmacy consultants, has become 
a common source of information regarding the dialytic clearance of drugs (Baillie and 
Mason, 2013). This excellent resource shows that only 10% of surveyed drugs have 
definitive dialyzability information for modern, high-flux hemodialysis (Velenosi and 
Urquhart, 2014). An additional 39% of drugs are classified as likely or unlikely dialyzed 
based solely on their physicochemical properties with no experimental data, whereas the 
remaining 50% of drugs have no available data. As a result, our current understanding of 
drug dialyzability is poor. Information regarding dialyzability currently falls into the 
following five categories: (1) nonexistent; (2) unsupported statements in product mono- 
graphs; (3) speculation based on a drug’s physicochemical characteristics; (4) 
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pharmacokinetic studies conducted before the modern era of hemodialysis; and (5) 
modern pharmacokinetic studies. Case reports of apparently successful dialysis in 
overdose settings provide some data, but the applicability of these reports to steady-state 
drug dosing is unknown. Overall, the dialyzability of cardiovascular drugs requires 
further research to better understand their inherent dialyzability, the clinical ramifications 
of dialyzability, and steps that can be taken to better the dosage of these important drugs 
in patients receiving hemodialysis. 
1.6.2 Drug Factors 
Removal of a drug from the body during hemodialysis depends on how readily 
the drug crosses the dialyzer and the amount of drug that is accessible in the blood over 
the course of a typical hemodialysis session. Diffusion across the dialysis membrane is 
limited primarily by a drug’s molecular size, for which molecular weight is a reasonable 
proxy. While the upper limit for modern high-permeability dialyzers is approximately 
12,000 Da, clearance rates decrease logarithmically with increasing size (Cheung and 
Leypoldt, 1997). Regardless of the physical size of the molecule, this characteristic is 
meaningful only for the unbound fraction of drug. Binding to serum albumin or 
erythrocytes increases a drug’s effective molecular weight far beyond the threshold of 
dialyzability. Therefore, the degree of protein binding can greatly reduce a drug’s 
dialyzability; however, protein binding is not a fixed characteristic and the dynamic 
equilibrium between bound and unbound drug is influenced by factors such as uremia, 
pH, and clinical circumstances, including whether patients are in a steady state on 
therapeutic dosing or have overdosed (Vanholder et al., 1988; Sue and Shannon, 1992; 
Kochansky et al., 2008). A drug’s volume of distribution also affects its dialyzability. 
19 
 
This parameter is determined by a drug’s lipid solubility and protein binding, and 
describes the extent to which a drug is distributed throughout the body compartments. 
Hemodialysis readily accesses contents of the extracellular fluid, particularly the blood 
compartment. Drugs with low volumes of distribution are largely found in these 
compartments and are more readily dialyzed than drugs whose large volumes of 
distribution indicate significant distribution to other tissues. 
1.6.3 Dialyzer and Dialysis Prescription Factors 
Understanding the role played by dialyzer characteristics and the prescription is 
important when trying to extrapolate the findings of older dialyzability studies to modern 
practice. The clearance rates of small-sized and medium-sized molecules are affected by 
a number of parameters that have changed with the advancement of hemodialysis. Small 
molecule clearance is largely determined by dialyzer surface area, which is generally 
larger in modern dialyzers (Daugirdas et al., 2012). Clearance of medium-sized 
molecules is determined more by dialyzer pore size, which has also increased over time 
with the introduction of synthetic membrane materials. This also provides higher 
ultrafiltration coefficients, resulting in better convective clearance (Bouré and Vanholder, 
2004). Newer dialysis prescriptions, such as quotidian dialysis protocols and 
hemodiafiltration, are moving modern hemodialysis practice even further away from the 
settings in which many drug dialyzabilities were originally determined. 
1.6.4 Determining Dialytic Clearance 
Further complicating drug dialyzability research is the method selected by 
investigators to determine dialytic clearance rates. The two main approaches are the 
arterial–venous (A-V) difference method and recovery clearance method (Lee et al., 
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1980; Uehlinger et al., 1996; Tieu et al., 2016). The majority of studies have applied the 
A-V difference method to determine dialyzability. This approach is limited by its 
inability to account for differences in drug distribution between plasma and red blood 
cells, as drug levels are generally measured only within the plasma compartment. The 
recovery clearance method is widely accepted as the superior approach to evaluate 
dialytic clearance because of its capacity to account for intradialytic hypotension, 
variations in dialysis membranes, and changes in nonrenal clearance during dialysis 
(Velenosi and Urquhart, 2014). However, many experimental designs lack analytical 
techniques sensitive enough to measure highly diluted drugs in total spent dialysate 
(around 120 L). Nonetheless, the recovery clearance method is accepted as superior to the 
A-V method and studies evaluating dialytic clearance should employ the recovery 
clearance method when possible to accurately characterize drug clearance by dialysis. 
 
1.7 Clearance of Cardiovascular Medications During 
Hemodialysis 
1.7.1 Beta-Adrenergic Receptor Blockers 
Epinephrine and norepinephrine are endogenous catecholamines that bind and 
activate adrenergic receptors to mediate different physiological responses. These 
receptors can be subdivided into alpha and beta receptors (Kidney Disease Outcomes 
Quality Initiative, 2004). Focusing on the beta subtype, beta-1 adrenoreceptors are 
primarily expressed in heart muscle and their activation generates an increase in 
atrioventricular nodal conduction, heart contractility, and heart rate. Localized in the 
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bronchial and peripheral vascular smooth muscle, activation of beta-2 adrenoreceptors 
causes dilation of vessels and bronchioles.  
Beta-adrenergic receptor antagonists (beta blockers) are an important class of 
medication for the management of hypertension and cardiovascular disease in patients 
receiving hemodialysis. The various classes of beta blockers differ in clinical benefit and 
adverse events, mainly due to their selectivity when binding endogenous receptors 
(Kidney Disease Outcomes Quality Initiative, 2004). Specifically, selective beta blockers 
are agents that preferentially antagonize beta-1 receptors (e.g. atenolol, bisoprolol and 
metoprolol) in order to improve cardiac function. Non-selective beta blockers are those 
that bind both beta-1 and beta-2 adrenoreceptors, which can lead to additional adverse 
events including bronchoconstriction and peripheral vascular symptoms. Carvedilol is a 
non-selective beta blocker that also antagonizes alpha receptors.  Left ventricular 
hypertrophy (Mark et al., 2006) and sudden cardiac death (McCullough, 2004) are 
common manifestations of heart disease in dialysis patients and the use of beta blockers 
has been associated with reductions in both the degree of hypertrophy and the risk of 
death in this patient population (Cice et al., 2003; Abbott et al., 2004; Hampl et al., 2005; 
Nakao et al., 2009; Matsue et al., 2013). With respect to dialyzability, the clearance of 
beta blockers during dialysis varies considerably, but the quality of evidence is low 
(Table 1.2) (Flouvat et al., 1980; Roux et al., 1980; Miki et al., 1991; Kanegae et al., 
1999). Minimally dialyzable beta blockers include carvedilol, which is 90% protein-
bound and difficult to detect in spent dialysate (Miki et al., 1991), and propranolol, which 
is also highly protein-bound. Bisoprolol is also likely to be of low dialyzability as 
outlined by previous review articles and industry sources (Table 1.3). At the more  
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Table 1.2. Dialyzability of beta blockers. 
Beta 
Blocker 
Molecular 
Weight 
(Daltons) 
Protein 
binding 
(%) 
Volume of 
distribution 
(L/kg) 
Dialyzability Data 
Specified Dialyzability 
Testing Conditions* 
Clearance 
during 
hemodialysis 
(ml/min)  
Reference 
Acebutolol 336 26 1.2 
Recovery method 
Single dose 
Dialyzer: cuprophane 
QD: 700 ml/min 
QB: 238 ml/min 
42.6 
Roux 
1980(55) 
Atenolol 266 10 4.2 
A-V Difference method 
Single dose 
Dialyzer: cuprophane 
QD: 700 ml/min 
QB: 236 ml/min 
42.6 
Flouvat 
1980(56) 
Bisoprolol 325 30 3 
A-V Difference method 
Single dose 
Dialyzer: polysulfone 
QD: ?  
QB: ?  
50.8 
Kanegae 
1999(57) 
Carvedilol 406 98 1.6 
A-V Difference method 
Single dose 
Dialyzer: ?  
QD: ?  
QB: ? 
“Not 
dialyzable” 
Miki 
1991(30) 
Metoprolol 267 10 3.2 No data No data - 
Nebivolol 405 98 ? No data No data - 
* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug 
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance 
is calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and 
venous (V) limbs of the dialysis machine and the blood flow rate.  
Abbreviations: QD, dialysate flow rate; QB, blood flow rate. 
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dialyzable end of the spectrum are a number of beta blockers with minimal protein 
binding, including acebutolol, atenolol, and metoprolol. A recently published 
retrospective cohort study compared the 90-day risk of mortality among patients on 
hemodialysis, who initiated a high versus low dialyzability beta blocker (Weir et al., 
2015).  This study demonstrated an increase in the risk of mortality among patients 
initiating one of the highly dialyzable agents (metoprolol, atenolol, or acebutolol) 
compared to those who started a low dialyzability agent (bisoprolol or propranolol). 
These findings suggest that dialyzability of beta blockers may be an important 
determinant of drug effectiveness in people receiving hemodialysis. Although this is 
thought provoking, shortcomings in the ability to definitively classify dialyzability leaves 
the door open for debate and is the primary rationale for experiments in this thesis. 
1.7.2 Angiotensin-Converting Enzyme Inhibitors and Angiotensin 
Receptor Blockers 
ACE inhibitors are commonly prescribed for hypertension, heart failure, or 
myocardial infarction because their use improves survival and prevents major 
cardiovascular events. The dialyzability of ACE inhibitors is incompletely characterized, 
but from existing data, dialyzability appears to vary significantly within this drug class 
(Fruncillo et al., 1987; Kelly et al., 1988; Verpooten et al., 1991; Gehr et al., 1993; 
Guerin et al., 1993; Fillastre et al., 1996; Yamada et al., 2003). Fosinopril is minimally 
dialyzable with a clearance rate during hemodialysis of only 4 ml/min, whereas enalapril 
and perindopril are highly dialyzable with clearance rates in excess of 60 ml/min. Other 
ACE inhibitors appear to have moderate levels of dialyzability (Supplementary Table C1, 
Appendix C) (Fruncillo et al., 1987; Kelly et al., 1988; Verpooten et al., 1991; Gehr et 
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al., 1993; Guerin et al., 1993; Fillastre et al., 1996; Yamada et al., 2003). The data 
supporting these categorizations are of reasonable quality with many studies conducted in 
the modern era using robust pharmacokinetic measurements. However, a significant 
amount of the data in this class was collected using low-efficiency, low-flux dialyzers 
and was determined using the inferior arterial-venous (A-V) difference method. 
Accordingly, it is difficult to compare dialyzability among drugs within this class because 
of the differences in methodology used to determine clearance. A recent study measured 
short-term mortality and cardiovascular end-points among patients on hemodialysis, who 
initiated ACE inhibitors of differing dialyzability (Weir et al., 2015). There was no 
difference in outcomes, which, among other factors, may have been the result of 
dialyzability misclassification. 
Angiotensin receptor blockers (ARBs) appear to express a more uniform level of 
dialyzability than ACE inhibitors (Supplementary Table C2, Appendix C) (Sica et al., 
1997; Pfister et al., 1999; Sica et al., 2000; Stangier et al., 2000; Tanaka et al., 2009). All 
commonly prescribed agents show very high levels of protein binding. In 
pharmacokinetic studies, ARBs are extremely difficult to detect in dialysate, and 
differences in ARB concentrations between blood entering and exiting the dialyzer are 
very low. This suggests that ARBs are not dialyzable to any meaningful extent. However, 
as is frequently the case, most studies with ARBs were not conducted with modern high-
flux, high-efficiency dialyzers. 
1.7.3 Calcium Channel Blockers 
Calcium channel blockers (CCBs) are commonly prescribed antihypertensive 
medications. Among patients receiving hemodialysis in the United States, approximately 
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50–65% are prescribed a CCB (St Peter et al., 2013; Shireman et al., 2014). 
Dihydropyridine CCBs (amlodipine, felodipine, nicardipine, and nifedipine) are much 
more commonly prescribed than nondihydropyridine CCBs (diltiazem and verapamil) (St 
Peter et al., 2013). Studies regarding the dialyzability of CCBs are few and were largely 
conducted prior to the modern era of hemodialysis (Supplementary Table C3, Appendix 
C) (Martre et al., 1985; Shah and Winer, 1985; Hanyok et al., 1988; Buur et al., 1991; 
Kungys et al., 2003). However, CCBs likely have minimal dialyzability as a result of 
high protein binding and large volumes of distribution. 
1.7.4 Antiplatelet Agents 
Patients receiving hemodialysis have an elevated risk of both thrombotic events 
and bleeding abnormalities (Rios et al., 2010). The National Kidney Foundation-Kidney 
Disease Outcomes Quality Initiative (NKF-KDOQI) recommends the use of antiplatelet 
agents to prevent cardiovascular events in patients with CKD. Although the associated 
risk of bleeding is well established, it is out-weighed by reductions in myocardial 
infarction rates among high-risk patients receiving hemodialysis (Palmer et al., 2013). 
Understanding the pharmacokinetics of antiplatelet drugs during dialysis is critically 
important to balance this risk-benefit relationship. However, there is a scarcity of data 
characterizing the dialyzability of these drugs. Aspirin has been shown to be moderately 
dialyzable with clearance rates ranging from 30 to 86 ml/min (Supplementary Table C4, 
Appendix C) (Doolan et al., 1951; Spritz et al., 1959; Kallen et al., 1966; Bern et al., 
1980; Jacobsen et al., 1988). These findings were observed in overdose settings, in which 
aspirin’s protein binding was likely to be less than its typical 99%. However, the binding 
of aspirin to albumin is relatively weak, and this may have contributed to the moderate 
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dialytic clearance observed (Kallen et al., 1966). No data on dialyzability are currently 
available for modern antiplatelet agents. 
1.7.5 Anticoagulant Agents 
Although anticoagulants have a proven benefit in the management of 
thromboembolic diseases in the general population, for patients with renal disease, there 
is little data available to guide treatment. With respect to dialyzability, anticoagulants 
vary considerably. Dabigatran, one of the new oral anticoagulants, is highly dialyzable 
with whole blood clearance rates in excess of 150 ml/min (Supplementary Table C5, 
Appendix C) (Ifudu and Dulin, 1993; Robson, 2000; Murray et al., 2004; Kalicki et al., 
2007; Wagner et al., 2011; Chang et al., 2013; De Vriese et al., 2015). In contrast, the 
other oral anticoagulants, including warfarin, apixaban, and rivaroxaban, are minimally 
cleared by hemodialysis. As shown in Supplementary Table C5 (Appendix C), there is a 
paucity of dialyzability data for injectable direct thrombin inhibitors, factor Xa inhibitors, 
and low-molecular-weight heparins. Although argatroban exhibited a 20% increase in 
clearance during hemodialysis, this difference was deemed to be clinically insignificant 
(Murray et al., 2004). Fondaparinux, a selective inhibitor of factor Xa, had a minimal 
dialytic clearance rate of 9.8 ml/min estimated from changes in anti-Xa activity (Kalicki 
et al., 2007). The lack of available information on anticoagulant removal by hemodialysis 
implicates a need to conduct further studies using high-efficiency, high-flux dialyzers. 
1.7.6 Cholesterol-Lowering Agents 
Over the past decade, there has been considerable controversy surrounding the 
value of cholesterol-lowering medications in patients receiving hemodialysis. Statin or 
statin and ezetimibe combination therapy is recommended for nondialysis-dependent 
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CKD patients, while dialysis patients should use these medications only if they were 
receiving them prior to dialysis initiation (Tonelli et al., 2014). As a class, the 
dialyzability of statins seems to be consistently minimal, which is reflective of their high 
protein binding and volumes of distribution. Accordingly, Launay-Vacher et al. (2005) 
has suggested that most statins can be administered at usual dosages any time before or 
after dialysis sessions. However, rosuvastatin had a dialytic clearance rate of 42 ml/min 
and pravastatin and its metabolites had higher and more variable rates of clearance, 
ranging from 38 to 81 ml/min, depending on the method used to determine dialyzability 
(Supplementary Table C6, Appendix C) (Gehr et al., 1997; Appel-Dingemanse et al., 
2002; Lins et al., 2003; Ichimaru et al., 2004; Birmingham et al., 2013). Ezetimibe has no 
available data but should be a focus of future research given its increasing use (Lu et al., 
2014), and the trend toward benefit among patients on dialysis observed in the SHARP 
trial (Baigent et al., 2011). 
 
1.8 Objectives and Hypothesis 
1.8.1 Rationale 
Of all comorbidities, cardiovascular disease has the greatest negative impact in 
CKD accounting for nearly 45% of mortalities in hemodialysis patients—an incidence 
10-20 times greater than the general population (Foley et al., 1998; Cheung et al., 2004; 
Collins et al., 2010). Over the past four decades, there have been vast advancements for 
the treatment of cardiovascular disease due in part to the emergence of beta blockers. 
This class of medication promotes cardiovascular improvements by decreasing blood 
pressure, heart rate, myocardial oxygen demand, arrhythmia, oxidative stress, and 
28 
 
improving left ventricular function (Lopez-Sendon et al., 2004). More importantly, the 
administration of beta blockers to reduce mortality in cardiovascular disease patients has 
been observed in numerous prospective randomized clinical trials (Hansson et al., 1999; 
Cice et al., 2003). It is based on the strength of these findings that beta blockers are 
administered to 64% of dialysis patients exhibiting cardiovascular complications, and 
have become a cornerstone treatment in CKD (Frankenfield et al., 2012).  
Many studies indicate altered medication pharmacokinetics in CKD, including 
both renal and non-renal drug elimination (Leblond et al., 2000; Nolin et al., 2009; 
Velenosi et al., 2012). Accordingly, expectations that beta blockers will deliver similar 
therapeutic efficacy in hemodialysis patients as compared with the general population is 
based on very little evidence. Most pharmacologic interventions have not included 
dialysis patients in their drug development process resulting in a lack of appropriate 
prescription recommendations (Ishani et al., 2004; Zhang et al., 2009; Frankenfield et al., 
2012; Matzke et al., 2015). In particular, drug dialyzability is likely to vary amongst 
different beta blockers and should be considered when they are administered to 
hemodialysis patients. For instance, the use of drugs that are highly dialyzable can result 
in sub-therapeutic plasma concentration during hemodialysis and lead to an increased risk 
for adverse clinical outcomes (Figure 1.1).  The unfortunate circumstance is that there is a 
paucity of available data to describe the dialyzability of beta blockers and many other 
currently marketed medications. Of the available information, most were obtained prior 
to implementation of high-flux, high-efficiency dialysis machines rendering many of the 
older studies irrelevant. The interdisciplinary approach to bridge pharmacology with 
clinical epidemiology uniquely positions us to determine conclusively the dialyzability of 
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beta blockers and its impact on cardiovascular outcomes. Data generated by this project 
are expected to be translated to future clinical practice guidelines, potentially optimizing 
pharmacotherapy and improving quality of life for chronic hemodialysis patients.  
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Figure 1.1. Potential effects of dialyzability on plasma drug concentration. 
We expect that the dialyzability between medications of the same drug class will differ 
substantially based on their physicochemical properties. Drugs that are highly dialyzed 
(○) will result in sub-therapeutic concentrations preventing their ability to mediate their 
intended pharmacological effect. Conversely, drugs that are minimally dialyzed (□) will 
remain within their therapeutic window due to lack of clearance during hemodialysis. 
Consideration to preferentially administer poorly dialyzed drugs to hemodialysis patients 
should be considered. 
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1.8.2 Hypothesis 
My governing hypothesis is that atenolol and metoprolol will be classified as “high 
dialyzability” beta blockers, while bisoprolol and carvedilol will be classified as “low 
dialyzability” beta blockers.  
1.8.3 Specific Objective 
Determine the pharmacokinetics and degree of dialyzability for the four most 
commonly prescribed beta blockers: atenolol, bisoprolol, carvedilol and metoprolol. 
Prior to investigating the effect of beta blocker dialyzability on clinical outcomes, 
the dialytic clearance rates were calculated and compared for definitive characterization 
of drug dialyzability. This was accomplished by conducting a pharmacokinetic, 4-way 
crossover study with ESRD patients receiving modern, high-flux hemodialysis. Ultra-
performance liquid chromatography coupled to mass spectrometry was used to measure 
plasma drug concentrations.  
Hypotheses on which beta blockers would be extensively or poorly dialyzed was 
determined after reviewing physicochemical properties of the drugs, consulting industry 
sources, and evaluating review articles. Statements regarding the dialyzability of each 
beta blocker are summarized in Table 1.3. In summary, we expected to find that atenolol 
and metoprolol will be extensively cleared by hemodialysis, while bisoprolol and 
metoprolol will be poorly dialyzed.     
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Table 1.3. Physicochemical properties and dialyzability statements for study beta blockers. 
Beta 
Blocker 
Physicochemical Properties 
Industry Statements Review Articles 
Expected 
Dialyzability Product 
Monographs 
Dialysis of Drugs 
2013a 
Levin et 
al. 2010 
Chazon 
and Jean 
2006 
Chen et 
al.2006 
Redon et 
al. 2010 
Atenolol 
Molecular Weight: 266 Daltons 
Water Solubility: 13,500 mg/L 
Protein Binding: 10% 
VD: 4.2 L/kg 
Moderately 
Dialyzable 
(20–50 %) 
Conventional HD: Yes 
Modern HD: Likely 
D D D D 
High 
Dialyzability 
Bisoprolol 
Molecular Weight: 325 Daltons 
Water Solubility: 2,240 mg/L 
Protein Binding: 30% 
VD: 3.0 L/kg 
Not 
Dialyzable 
Conventional HD: Yes 
Modern HD: No Data 
ND ND ND ND 
Low 
Dialyzability 
Carvedilol 
Molecular Weight: 406 Daltons 
Water Solubility: 0.583 mg/L 
Protein Binding: >98% 
VD: 1.6 L/kg 
Not 
Dialyzable 
Conventional HD: No 
Modern HD: Unlikely 
ND ND ND ND 
Low 
Dialyzability 
Metoprolol 
Molecular Weight: 267 Daltons 
Water Solubility: 16,900 mg/L 
Protein Binding: 10% 
VD: 3.2 L/kg 
No 
Statement 
Conventional HD: Yes 
Modern HD: Likely 
D D D ND 
High 
Dialyzability 
a Annual guidelines published by Renal Pharmacy Consultants, LLC (Saline, Michigan, USA). Dialyzability based on scientific and industry data 
VD Volume of distribution. 
HD Hemodialysis. 
Yes Dialysis was found to enhance drug clearance from previously published studies.  
No Dialysis was not found to enhance drug clearance from previously published studies.  
No Data No data or assumptions from physicochemical properties exist to describe drug dialyzability. 
Likely Drug is likely to be cleared by hemodialysis based on physicochemical parameters, but no data exists.  
Unlikely Drug is unlikely to be cleared by hemodialysis based on physicochemical parameters, but no data exists. 
D Drug is listed as dialyzable in corresponding review article. 
ND Drug is listed as not dialyzable in corresponding review article. 
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2 MATERIALS AND METHODS 
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2.1 Characterizing Beta Blocker Dialyzability 
2.1.1 Study Design and Participant Eligibility 
Eight hemodialysis patients were prospectively recruited from the London Health 
Sciences Centre (LHSC) to participate in a clinical pharmacokinetic study on the 
dialyzability of commonly used beta blockers. This study was approved by the Health 
Sciences Research Ethics Board at Western University (Approval Number 104909). The 
sample size was determined based on previously completed dialyzability studies using 
older, conventional dialyzers (Flouvat et al., 1980; Campese et al., 1985; Payton et al., 
1987; Buttazzoni et al., 2006; Sowinski et al., 2008). The study was an open-label, 4-way 
crossover trial of the four most commonly prescribed beta blockers in Ontario: atenolol 
(50 mg), bisoprolol (5 mg), carvedilol (6.25 mg), and metoprolol (50 mg). A randomly 
selected, single oral dose of one of the four beta blockers was administered to the subjects 
4 hours prior to hemodialysis initiation. A washout period of at least 2 days was required 
before subjects received the next beta blocker, and this process continued until all 4 beta 
blockers were administered to all subjects. Four hours following drug administration, 
dialysis was initiated according to the patient’s regular treatment. During dialysis, blood 
samples were collected from the arterial and venous ports at 6 different time points for 
each patient. For subjects who received dialysis for 4 hours, blood was drawn 0.0, 0.5, 
1.0, 2.0, 3.0, and 4.0 hours after dialysis initiation.  For subjects treated with dialysis for 
3.5 hours, blood samples were collected 0.0, 0.5, 1.0, 1.5, 2.5, and 3.5 hours after starting 
dialysis. Lastly, subjects who were prescribed a 3 hour dialysis duration had blood drawn 
0.0, 0.5, 1.0, 1.5, 2.5, and 3.0 hours after dialysis initiation. Total spent dialysate was 
recovered throughout the entirety of the hemodialysis treatment by diverting the waste 
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from the drain to a 200 L, food-grade plastic barrel. All samples were obtained for 
measurement of beta blocker concentrations. 
Subject eligibility for study enrollment was determined by the following inclusion 
criteria: (1) at least 18 years of age, and (2) patients were on standard, thrice weekly 
hemodialysis for at least 90 days prior to first study session. Subjects were excluded from 
study enrollment if any of the following exclusion criteria was evident: (1) significant 
gastrointestinal or liver disease, (2) body mass index greater than 40 kg/m2, (3) 
prescription of contraindicated medications (amiodarone, digoxin, phenytoin, quinidine, 
and others) or prior adverse drug reactions to beta blockers, and (4) bradycardia (heart 
rate less than 50 bpm) or hypotension (systolic blood pressure less than 100 mmHg) 
within the last 2 weeks prior to study commencement. Appendix D highlights in greater 
detail the specific inclusion and exclusion criteria applied to the subject screening 
process. Patients who did meet the eligibility criteria were enrolled on the provision of 
informed written consent in accordance with the Declaration of Helsinki.  
2.1.2 Clinical Data Collection and Follow-Up 
Demographic information was collected at the time of study enrollment. Patient 
information on their current medications, health status, and hemodialysis treatment plan 
was obtained by interview and review of medical records. Blood samples from the 
arterial port before and after the hemodialysis session were obtained for hematocrit 
assessment conducted by the London Laboratory Services Group using standard methods 
(London, ON.). Subjects were monitored for adverse events throughout their dialysis 
session, and adjustments to hemodialysis were made by healthcare professionals 
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according to standard hemodialysis protocol. The study period was from February 2015 
to March 2016. 
2.1.3 Chemical Reagents and Drugs 
Atenolol (50 mg, Teva Pharmaceuticals Ltd.), bisoprolol fumarate (5 mg, Apotex 
Inc.), PMS-carvedilol (6.25 mg, Pharmascience Inc.), and metoprolol tartrate (50 mg, 
Mylan Pharmaceuticals Inc.) administered to subjects in the study were purchased from 
the pharmacy at London Health Sciences Centre (LHSC, London, ON). Atenolol, 
bisoprolol hemifumarate, carvedilol, metoprolol, atenolol-d7, bisoprolol-d7 
hemifumarate, carvedilol-d3, and metoprolol-d7 standards used for drug level analysis 
were purchased from Toronto Research Chemicals (Toronto, ON).  
2.1.4 Beta Blocker Extraction and Liquid Chromatography 
Blood samples were centrifuged at 2000g for 10 minutes within one hour of 
collection. Plasma was separated from blood cells and subsequently stored with dialysate 
samples at -80°C until analysis. Plasma and dialysate concentrations of atenolol, 
bisoprolol, carvedilol, and metoprolol were determined using solid phase extraction 
(SPE) followed by ultra-performance liquid chromatography coupled with quadrupole 
time-of-flight mass spectrometry (UPLC-QToFMS). Beta blocker extraction from plasma 
and dialysate samples were conducted with SPE cartridges (C18, Strata-X Polymeric 
Reversed Phase 33 µm) obtained from Phenomenex (Torrance, CA) and conditioned 
according to manufacturer’s specifications. Atenolol-d7, bisoprolol-d7, carvedilol-d3, 
and metoprolol-d7, all at 50 ng/mL, were used as internal standards for drug 
quantification. Plasma, dialysate, and internal standards were passed across the SPE 
cartridges under a vacuum pressure of less than 250 mmHg. Cartridges were washed with 
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1 mL of nano-pure water followed by 1 mL of 20% methanol in water, and analytes were 
eluted into clean glass test tubes with 1 ml of methanol solution containing 0.1% 
trifluoroacetic acid. Eluents were dried in a 40°C water bath using an Organomation N-
EVAPTM nitrogen evaporator (Berlin, MA) which was followed by sample reconstitution 
in mobile phase. Dried eluents that contained carvedilol from plasma extractions were 
concentrated 10-fold to ensure adequate compound detection, while samples containing 
other beta blockers were not concentrated before analysis. Dried eluents from dialysate 
extractions were concentrated 100-fold to ensure adequate beta blocker signal during 
analysis. Reconstituted samples were injected at a volume of 5 µL with a flow rate of 0.7 
mL/min on a Phenomenex Kinetex C8 column (1.7 µm particle size, 50 x 2.1 mm) for 
analyte separation. The Waters ACQUITY UPLCTM I-Class system (Waters, Milford, 
MA) autosampler maintained the column temperature at 40°C. Water (A) and acetonitrile 
(B), both containing 0.1% formic acid, were the mobile phase solutions used for 
compound elution. The UPLC elution parameters were as follows: 0.00–0.20 min, 2% B; 
0.20–1.50 min, 2–80% B; 1.50–2.50 min, 80% B; and 2.51–3.51 min, 2% B. 
2.1.5 Beta Blocker Analysis with Mass Spectrometry 
Mass spectrometry was conducted using a Waters XevoTM G2S-QTofMS. Beta 
blockers were measured using positive electrospray ionization (ESI) mode. The capillary 
and cone voltages were set at 0.5 kV and 40 V, respectively and a source temperature of 
150°C was maintained. The desolvation gas flow was 1200 L/h at a temperature of 
650°C, and the cone gas flow was 50 L/h. The data was acquired in centroid mode using 
an MSE method allowing for both MS and MS/MS fragmentation during a single run. 
Acquisition samples were measured in positive polarity with extended dynamic range and 
38 
 
the analyzer mode set to resolution. Both functions 1 (low energy collision) and 2 (high 
energy collision) of the centroid method acquired data within a mass range of 50 to 1200 
Da and a scan time of 0.05s. Collision energy for function 1 of the MSE method was set 
at 0V, while function 2 was ramped from 15–50 V. Function 3 acquired lockspray to 
maintain accurate mass detection and reproducibility. The lockmass consisted of leucine-
enkephalin (1ng/µL) set at a flow rate of 10 µL/min. A lockspray frequency of 10s was 
applied and data was averaged over 3 scans.  Acquisition of data was controlled by 
Waters MassLynx v4.1 software and peak integration of sample chromatograms were 
conducted with QuanLynx software (Waters, MA, USA). 
2.1.6 Determining Dialytic Clearance 
The two main methods to evaluate the clearance of medications during 
hemodialysis are the arterial-venous (A-V) difference method (1) and recovery clearance 
method (2), which are described by the following equations (Lee et al., 1980; Uehlinger 
et al., 1996; Tieu et al., 2016): 
(1) CLA-V = QP [(Aconc – Vconc) / Aconc] 
QP = QB (1 – Hct) 
Where CLA-V is A-V difference clearance, QP is plasma flow rate, QB is blood 
flow rate, Hct is hematocrit, Aconc is arterial plasma drug concentration, and Vconc is 
venous plasma drug concentration. 
(2) CLR = Rdrug / AUC0-T 
Where CLR is dialyzer clearance, Rdrug is total amount of drug recovered in 
dialysate calculated by multiplying the dialysate drug concentration by total spent 
dialysate volume, and AUC0-T is area under the plasma concentration-time curve during 
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dialysis. The AUC0-T was calculated by the trapezoidal method using GraphPad Prism 
(version 6.01 for Windows; GraphPad Software, San Diego, CA). 
2.1.7 Other Pharmacokinetic Parameters 
The following pharmacokinetic parameters were determined by applying different 
equations as outlined by Rowland and Tozer (1995): (3) total clearance, (4) non-dialytic 
clearance, (5) elimination half-life, (6) fraction of total clearance due to dialysis, (7) 
fraction of drug eliminated during dialysis, and (8) post-dialysis supplemental dose. 
(3) CLTotal = (CT=0*VD*FU)/ AUC0T 
Where CLTotal is the total clearance during the hemodialysis session, CT=0 is the 
arterial beta blocker concentration at the beginning of dialysis, VD is the volume of 
distribution, FU is the fraction of drug unbound, and AUC0T is the area under the plasma 
concentration-time curve during dialysis. 
(4) CLNon-dialysis = CLTotal – CLDialysis 
Where CLNon-dialysis is drug clearance due to non-dialytic mechanisms, CLTotal is 
total drug clearance, and CLDialysis is dialytic clearance 
(5) T1/2 =  0.693/kD 
Where T1/2 is the elimination half-life of the drug during hemodialysis, and kD is 
the elimination rate constant as determined by calculating the slope of the line after 
plotting the logarithm of plasma drug levels versus time on hemodialysis. 
(6) FDialysis = CLDialysis / CLTotal 
Where FDialysis is the fraction of total drug clearance occurring by dialysis 
(7) FDrug = FDialysis*(1 – e –KD*T) 
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Where FDrug is the fraction of drug initially in the body eliminated during 
hemodialysis, kD is the elimination rate constant during hemodialysis, and T is the length 
of the hemodialysis session 
(8) Supplemental Dose = CT=0*VD*(e–KE*T – e–KD*T) 
Where kE is the elimination rate constant of the beta blocker in CKD patients 
2.1.8 Statistical Analysis 
All statistical analysis was performed using GraphPad Prism (version 6.01 for 
Windows; GraphPad Software, San Diego, CA). Statistical differences between atenolol, 
bisoprolol, carvedilol and metoprolol treatments were assessed by one-way analysis of 
variance (ANOVA) followed by Tukey’s post-hoc test. Results are presented as mean ± 
SD and a p-value less than 0.05 was considered statistically significant.  
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3 RESULTS
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3.1 Assay Validation and Performance  
In order to determine the concentration of beta blockers found in clinical samples, 
a UPLC-MS method was developed and validated to quantify atenolol, bisoprolol, 
carvedilol and metoprolol in plasma and dialysate. Sample preparation with SPE 
cartridges were assessed for beta blocker recovery by comparing the mean concentration 
of 5 analytical replicates to the nominal concentration. The percent recovery of atenolol, 
bisoprolol, carvedilol, and metoprolol were 101%, 112%, 93%, and 112%, respectively.  
In plasma, a calibration curve over the concentration range of 0.488–500.0 ng/ml 
was created. Patient plasma concentrations for each beta blocker were within this range 
and suitable for sample analysis. Using a signal-to-noise ratio greater than 3:1, the lower 
limit of detection (LLOD) for atenolol, bisoprolol, carvedilol, and metoprolol in plasma 
was 0.0153, 0.0305, 0.4883 and 0.0305 ng/mL, respectively. In dialysate, a calibration 
curve of 0.488–500.0 ng/mL was used for sample analysis. Atenolol, bisoprolol, and 
metoprolol levels in total spent dialysate were quantifiable using this range of 
concentrations; however, most dialysate samples containing carvedilol were below the 
lower limit of quantification (LLOQ) due to minimal clearance by dialysis. As a result, 
the intra-day accuracy and precision was assessed using 5 analytical replicates of the 
lowest concentration on the dialysate calibration curve. Accuracy, expressed as a bias 
percentage, was determined by comparing the mean measured concentration to the 
nominal concentration. Precision was determined by calculating the coefficient of 
variation (CV) percentage of the 5 analytical replicates. Using a signal-to-noise ratio of at 
least 10:1, the LLOQ of the calibration curve displayed acceptable accuracy (< 15%) and 
precision (< 10%) for all beta blockers. Specifically, the bias and CV were 4.2% and 
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1.1% for atenolol, 2.0% and 2.7% for bisoprolol, -6.0% and 12.5% for carvedilol, and 
1.9% and 1.5% for metoprolol. The LLOD for atenolol, bisoprolol, and metoprolol was 
0.0076 ng/mL while carvedilol had a LLOD of 0.0305 ng/mL, all of which were 
determined using a signal-to-noise ratio of at least 3:1.  
 
3.2 Baseline Characteristics of Subjects 
In total, eight ESRD patients requiring chronic hemodialysis were enrolled and 
each patient had received hemodialysis treatment for greater than three months. Beta 
blocker treatments were well tolerated by all study participants and no serious adverse 
drug reactions occurred. No abnormalities in heart rate and blood pressure were observed 
during the course of the study. Every subject completed the pharmacokinetic 4-way 
crossover trial and all but one of the patients was male (Table 3.1). The mean age of 
subjects was 58 years (ranging from 28 to 80 years), mean height was 1.70 m and mean 
weight was 95.1 kg. The mean body mass index was 32.6 kg/m2. The primary causes for 
CKD diagnosis were diabetes mellitus (n=1), hypertension (n=1), rapidly progressive 
glomerulonephritis (n=1), polycystic kidney disease (n=1), reflux nephropathy (n=1), and 
a combination of both diabetes and hypertension (n=3). Hemodialysis sessions ranged 
from 3 to 4 hours with a treatment interval of 3 times per week. Fractional clearance of 
urea (Kt/V), also known as dialysis adequacy, has been shown to have a strong, positive 
correlation with patient mortality (Lowrie et al., 1981; Gotch and Sargent, 1985; Shinzato 
et al., 1997). The National Kidney Foundation has made recommendations for a 
minimum delivered Kt/V value of 1.2–1.4 as higher target levels do not improve survival, 
while lower values increase risk for patient morbidity (Lowrie et al., 1981; Shinzato et 
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al., 1997; Eknoyan et al., 2002; National Kidney Foundation, 2015). Four of the eight 
subjects had Kt/V values below the recommended target (Table 3.1). In regards to 
vascular access, 4 patients had a central catheter insertion at the right internal jugular vein 
while the other 4 subjects had an arteriovenous fistula in place for blood removal and 
return. All but one patient had higher hematocrit levels post-dialysis as compared to their 
pre-dialysis state. 
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3.3 Dialyzability of Beta Blockers in Chronic Hemodialysis 
Patients 
The effective blood flow rate and pre-dialysis hematocrit measurements for each 
subject is shown in Table 3.1. These two variables were combined with the difference in 
beta blocker concentrations in the arterial and venous ports to calculate dialyzability 
values using the arterial-venous difference equation (Equation 1). As a result, the dialytic 
clearance rates for atenolol, bisoprolol, and metoprolol are (mean ± SD) 162.1 ± 22.2, 
88.9 ± 15.7, and 106.6 ± 18.1 mL/min, respectively (Figure 3.1). The rates of removal for 
these 3 beta blockers are significantly higher than carvedilol at 17.3 ± 14.8 mL/min (P < 
0.01). Additionally, the clearance of atenolol during hemodialysis is considerably 
elevated when compared to bisoprolol and metoprolol (P < 0.01), whereas bisoprolol and 
metoprolol are not significantly different from each other.  
Collection and analysis of plasma samples over the duration of the hemodialysis 
session allowed us to create plasma concentration-time profiles (Figure 3.2) and 
determine the level of beta blocker exposure for each subject (reported as AUC0T). For 
atenolol, bisoprolol, carvedilol and metoprolol, patient drug exposure was 827.9, 180.7, 
150.5, and 106.9 ng∙h/mL. The amount of beta blocker measured in total spent dialysate 
was 3.67 mg, 0.46 mg, 0.00 mg, and 0.56 mg, respectively. AUC values and the total 
amount of drug recovered in dialysate were applied to the recovery clearance method 
(Equation 2) to produce comparable dialytic clearance rates between atenolol and 
metoprolol at 71.8 ± 20.5 and 86.4 ± 27.8 mL/min, respectively (Figure 3.3). The 
clearance for both of these beta blockers during hemodialysis was considerably higher 
than bisoprolol at 43.7 ± 8.8 mL/min (P < 0.05 compared to atenolol and P < 0.01 
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compared to metoprolol). When compared to the other beta blockers, carvedilol displayed 
a substantially lower clearance rate at 0.2 ± 0.6 mL/min (P < 0.01)  
Based on data from the recovery clearance method, atenolol and metoprolol can 
be classified as beta blockers with “high dialyzability”. Similar findings from both the A-
V difference and recovery clearance methods classifies bisoprolol as a drug of “moderate 
dialyzability”, while carvedilol can be categorized as a “low dialyzability” beta blocker. 
These beta blocker classifications were incorporated into the study design for a 
provincial-wide, population-based retrospective cohort study. 
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Figure 3.1. Clearance rate of beta blockers during hemodialysis calculated using the 
arterial-venous difference equation. 
Dialytic clearance values for the four beta-blockers (atenolol, bisoprolol, carvedilol, and 
metoprolol) during hemodialysis in end-stage renal disease patients. Plasma 
concentration of beta blockers were determined using ultra-performance liquid 
chromatography coupled to a quadrupole time-of-flight mass spectrometer (UPLC-
QToFMS) and dialyzability was calculated using the arterial-venous (A-V) difference 
method. Results are presented as mean ± SD with n=8 for each treatment group. # P < 
0.01 relative to atenolol, and * P < 0.01 for carvedilol relative to all other beta blockers. 
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Figure 3.2. Beta blocker plasma concentration-time profiles of end-stage renal 
disease patients during hemodialysis. 
Plasma concentration-time profiles of atenolol (A), bisoprolol (B), carvedilol (C), and 
metoprolol (D) during hemodialysis in end-stage renal disease patients. Each subject 
received a single oral dose of a beta-blocker four hours prior to dialysis onset. Plasma 
concentration of beta blockers were determined using ultra-performance liquid 
chromatography coupled to a quadrupole time-of-flight mass spectrometer (UPLC-
QToFMS). Results are presented as mean ± SD with n=8 for all treatment groups. 
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Figure 3.3. Clearance rate of beta blockers during hemodialysis calculated using the 
recovery clearance equation. 
Dialytic clearance values for the four beta-blockers (A) atenolol, (B) bisoprolol, (C) 
carvedilol, and (D) metoprolol, during hemodialysis in end-stage renal disease patients. 
Plasma concentration of beta blockers were determined using ultra-performance liquid 
chromatography coupled to a quadrupole time-of-flight mass spectrometer (UPLC-
QToFMS) and dialyzability was calculated using the recovery clearance method. Results 
are presented as mean ± SD with n=8 for each treatment group. * P < 0.01 for carvedilol 
relative to all other beta blockers, # P < 0.05 relative to bisoprolol, and ## P < 0.01 
relative to bisoprolol. 
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3.4 Additional Pharmacokinetic Parameters 
Additional pharmacokinetic parameters were investigated for each beta blocker 
during hemodialysis (Table 3.3). Literature values for volume of distribution (VD), 
fraction of drug unbound (FU) and elimination rate constant (kE) in CKD patients not 
being treated with HD were used to determine the total clearance of beta blockers. For 
atenolol, the reported value of VD is 0.90 L/kg with an FU of 0.84–0.94 and kE of 0.0225 
h-1 (Kirch et al., 1981; AstraZeneca Canada Inc., 2011). The VD, FU and kE of bisoprolol 
are 1.84 L/kg, 0.70, and 0.0286 h-1, respectively (Kirch et al., 1987; Payton et al., 1987; 
Apotex Inc., 2004). In non-CKD patients, carvedilol has a VD of 1.68 L/kg with less than 
2% of the drug bound to plasma proteins (von Mollendorff et al., 1987; Auro Pharma 
Inc., 2013). The kE observed in patients with advanced renal insufficiency was 0.104 
(Gehr et al., 1999). Lastly, the VD, FU and kE for metoprolol are 3.50 L/kg, 0.90 and 
0.139 h-1, respectively (Jordo et al., 1980; Novartis Pharma, 2015). 
These variables were used to calculate the total clearance of each beta blocker 
during dialysis (Table 3.2). Metoprolol has a total clearance of 2364.4 mL/min, which is 
markedly higher when compared to atenolol (524.0 mL/min), bisoprolol (700.3), and 
carvedilol (810.8 mL/min, P < 0.01). The proportion of clearance due to dialytic 
elimination is 0.14 for atenolol, 0.07 for bisoprolol, 0.00 for carvedilol and 0.04 for 
metoprolol. During dialysis, the elimination half-life of atenolol was 3.88 hours 
corresponding to a 54% reduction in plasma concentration. Bisoprolol concentration 
decreased by 33% over the dialysis session producing a half-life of 7.00 hours, which is 
considerably longer when compared to the other beta blockers (P < 0.01). Plasma 
concentration of carvedilol decreased by 34%, which corresponds to a half-life of 3.84 
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hours. Lastly, the half-life of metoprolol during hemodialysis was 2.85 hours which was 
determined from an overall 61% reduction in plasma concentration.  
After the hemodialysis session, the mean supplemental dose for bisoprolol as a 
percentage of the initial administered dose is 38% (1.9 mg). This is not significantly 
different from atenolol at 23% (11.4 mg); however, bisoprolol does require a markedly 
higher post-dialysis dose as compared with carvedilol at 14% (0.87 mg) and metoprolol 
at 5.5% (2.7 mg, P < 0.05).  
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Table 3.2 Pharmacokinetic parameters of beta blocker treatments during hemodialysis.  
Hemodialysis time of subjects may vary depending on physician recommendations. 
Beta Blocker 
Atenolol 
(50mg) 
Bisoprolol 
(5mg) 
Carvedilol 
(6.25mg) 
Metoprolol 
(50mg) 
Amount Dialyzed  
(% of initial dose) 
7.34 ± 2.87 Ω 9.30 ± 4.92Ω 0.00 ± 0.00 1.03 ± 0.68 
AUC0T (ng∙h/mL) 827.9 ± 146.5*  180.9 ±  99.31 89.56 ±  77.84 106.9 ±  90.6 
CLTotal (mL/min) 524.2 ± 93.1 700.3 ± 170.7 810.8 ± 275.3 2364.4 ± 560.0* 
CLNon-dialysis 
(mL/min) 
452.4 ± 93.2 656.6 ± 170.4 810.6 ± 275.4 2278.0 ± 548.7* 
T1/2 on 
hemodialysis (h) 
3.88 ± 0.86 7.01 ± 2.12* 3.84 ± 0.85 2.85 ± 0.81 
FDialysis 0.14 ± 0.05* 0.07 ± 0.02 0.00 ± 0.00 § 0.04 ± 0.01 
FDrug 0.07 ± 0.02* 0.02 ± 0.01 0.00 ± 0.00 § 0.02 ± 0.01 
Supplemental Dose 
as % of initial dose 
(dose in mg) 
22.8 ± 5.6 
(11.4 ± 2.8) 
38.0 ± 20.6 Ω 
(1.90 ± 1.03) 
13.9 ± 17.1 
(0.87 ± 1.07) 
5.5 ± 2.9 
(2.74 ± 1.45) 
AUC0T is the area under the concentration-time curve during hemodialysis 
CLTotal is total clearance of the drug during hemodialysis (dialytic and non-dialytic 
components) 
CLNon-dialysis is clearance of the drug due to non-dialytic mechanisms 
T1/2 on hemodialysis is half-life of the drug during hemodialysis 
FDialysis is fraction of clearance due to hemodialysis 
FDrug is fraction of drug initially in body eliminated by hemodialysis 
Supplemental Dose is the dose of beta blocker required after hemodialysis to reach the 
drug level that was observed in the patient prior to dialysis. 
Data are presented as mean ± SD with n=8 for each beta blocker group.  
Ω P < 0.01 relative to carvedilol and metoprolol 
* P < 0.01 relative to all other beta blockers  
§ P < 0.01 for carvedilol relative to bisoprolol and metoprolol 
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4 DISCUSSION
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4.1 Summary of Results 
4.1.1 Clinical Pharmacokinetic Study 
In this thesis, we outlined a dialyzability study design and various 
pharmacokinetic equations that were applied to a cohort of hemodialysis patients in order 
to define clinically-relevant parameters pertaining to dialytic elimination of drugs. With 
only 10% of currently marketed medications having definitive dialyzability information 
based on experimental data (Velenosi and Urquhart, 2014), this study was conducted with 
a primary focus on determining the dialytic clearance of the four most commonly 
prescribed beta blockers in Ontario. Additionally, many of the studies that do exist have 
become considerably outdated due to the nearly universal switch from “conventional” to 
“high-flux” dialysis membranes. This study is the first to assess beta blocker dialyzability 
using the recovery clearance method in ESRD patients during modern, high-flux, high-
efficiency hemodialysis treatment.  
As expected, our findings demonstrate that both atenolol and metoprolol are 
extensively removed during hemodialysis. Despite renal excretion accounting for only 
5% of metoprolol clearance (Regardh and Johnsson, 1980), both atenolol and metoprolol 
have physicochemical properties that enable them to be readily dialyzed. For instance, 
both drugs are only 10% bound to plasma proteins, are highly water soluble, and have 
similarly low molecular weights at 270 Da—well below the upper limit of 12,000 Da for 
modern dialyzers (McAinsh, 1977; Regardh and Johnsson, 1980; Cheung and Leypoldt, 
1997). Despite metoprolol being the second most frequently used antihypertensive agent 
in National Health and Nutrition Examination Survey (NHANES) 2009 to 2010 (Gu et 
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al., 2012), no previous studies have been conducted to determine its dialyzability. As for 
atenolol, the A-V difference method applied by Flouvat et al. (1980) produced a 
clearance rate of 42.6 mL/min for ESRD patients on a coil kidney dialysis with 
cuprophane membrane. Using the same equation, the contemporary, high-flux 
polysulfone based dialyzers prescribed to subjects in our study generated a substantially 
higher dialytic clearance of 162.1 mL/min. When the more reliable recovery clearance 
equation was applied, the dialyzability of atenolol at 71.8 mL/min was still higher than 
the value determined by Flouvat and colleagues (1980). These findings support the notion 
that older dialyzability studies are becoming unreliable in their ability to provide 
pharmacokinetic information when treating patients with modern dialyzers.   
As for carvedilol, its physicochemical properties are highlighted by a larger 
volume of distribution and decreased water solubility, both of which would suggest 
minimal or low dialytic clearance (GlaxoSmithKline Inc.). However, the primary factor 
causing its negligible dialytic clearance is its extensive protein binding at 98% (Varin et 
al., 1986). This conclusion was also drawn by Miki et al. (1991) after finding a non-
significant difference in carvedilol levels between the arterial and venous ports of dialysis 
patients. Although carvedilol displayed a small but measurable value of dialytic clearance 
when using the A-V difference equation in our study, the recovery clearance method 
indicated a virtually null contribution from dialysis to its elimination. A low dialyzability 
was similarly expected for bisoprolol after consulting the dialysis of drugs guidelines and 
various peer-reviewed articles (Table 1.3). Surprisingly, our study indicates that 
bisoprolol is moderately dialyzable regardless of the method used to determine its 
clearance rate. Kanegae et al. (1999) found a comparable dialytic clearance of 50.8 
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mL/min for patients who were also prescribed polysulfone-based dialyzer membranes. 
This finding of moderate dialyzability is reflective of bisoprolol’s intermediate 
physicochemical properties as compared to carvedilol and atenolol. Specifically, 
bisoprolol has a mild degree of protein binding (30%) as well as balanced lipophilic and 
hydrophilic components in its molecular structure (Buhring et al., 1986; Leopold, 1986). 
Further evidence showing the impact that modern dialyzers have on drug 
dialyzability can be derived from comparisons of elimination half-life. For severe renal 
impairment patients not yet receiving dialysis, the half-life of atenolol, bisoprolol, 
carvedilol and metoprolol are approximately 70, 24, 7 and 5 hours, respectively (Flouvat 
et al., 1980; Jordo et al., 1980; Kirch et al., 1987; Gehr et al., 1999). Although very few 
studies have evaluated dialytic clearance, the half-life for these beta blockers have been 
previously reported for patients on older conventional dialyzers. The half-life of atenolol 
is shortened to only 7 hours during conventional hemodialysis (Campese et al., 1985; Fox 
and Investigators, 2003), which was found to be further reduced to 3.9 hours due to the 
use of modern dialyzers in our study. In order to maintain the pharmacological effect of 
atenolol when patients transition from ESRD to dialysis, an increase in dosage is required 
and changing intake of atenolol to a post-dialysis period should be considered. Plasma 
concentrations of bisoprolol in patients using a polysulfone dialyzer were reduced by 
25% during hemodialysis (Kanegae et al., 1999), similar to what we determined in our 
study. The resulting half-life was 7 hours—over 70% shorter than what is observed in 
non-dialysis ESRD patients. For carvedilol and metoprolol, their half-life in CKD 
patients do not differ largely from the values reported in patients with normal functioning 
kidneys (Regardh and Johnsson, 1980). However, the modern hemodialyzers used in this 
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study did result in a minor decrease in metoprolol half-life, which corresponds to more 
than half of the drug being eliminated within a 4 hour dialysis session.  
Plasma concentration-time profiles of each beta blocker during the hemodialysis 
session were evaluated to assess drug exposure. The variability in plasma drug levels at 
each time point between patients was noticeably lower for atenolol than other beta 
blockers. This disparity may be explained by differences in the route of elimination for 
each drug. Little to none of atenolol clearance can be attributed to hepatic metabolism, 
suggesting that dialysis is the primary mechanism of atenolol removal in kidney failure 
patients (AstraZeneca Canada Inc., 2011). Since the hemodialysis treatment plan and 
dialyzer membranes prescribed between subjects were similar, the more consistent drug 
levels observed were as expected. In contrast, metoprolol is extensively metabolized by 
the drug metabolizing enzyme, cytochrome P450 2D6 (CYP2D6), with only 5% of the 
drug eliminated through renal excretion (Regardh and Johnsson, 1980). Interindividual 
differences in plasma concentration of metoprolol may be due to the large phenotypic 
variability in CYP2D6 genotype and the associated categorizations of people into poor, 
intermediate, extensive or ultra-rapid drug metabolizers (Zanger et al., 2004). Rau et al. 
(2002) demonstrated that poor and intermediate metabolizers on long-term metoprolol 
treatment had plasma concentrations 6- and 4-fold higher than extensive metabolizers, 
respectively. A recently completed meta-analysis of CYP2D6 phenotypes similarly 
showed that poor metabolizers had a 5- and 13-fold increase in metoprolol exposure as 
compared to extensive and ultra-rapid metabolizers, respectively (Blake et al., 2013). 
Despite this variability in pharmacokinetics, there still exist controversial findings as to 
whether CYP2D6 genotyping can offer clinical benefit to metoprolol dosing in patients. 
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Shin and Johnson (2007) have stated that the overall pharmacological efficacy and 
toxicity of metoprolol are not influenced by CYP2D6 genotype, while Swen et al. (2011) 
have reported a necessity to alter metoprolol dosage in heart failure patients depending on 
their CYP2D6 metabolizer phenotype. In our study, individual plasma profiles of study 
subjects demonstrated good correlation with a one-phase decay model, reaffirming that 
metoprolol is highly cleared by hemodialysis.  
Bisoprolol has a balanced mechanism of clearance with equal contributions from 
both renal and non-renal pathways (Leopold et al., 1982). The main drug metabolizing 
enzymes involved in bisoprolol elimination are CYP3A4 and CYP2D6 (Horikiri et al., 
1998). However, variations in oral clearance, apparent volume of distribution, and plasma 
concentration are not well correlated with CYP2D6 genotypes (Nozawa et al., 2005; 
Taguchi et al., 2005). An in vitro study using intestinal epithelial cells indicates 
temperature and pH dependent alterations in the rate and extent of bisoprolol uptake 
(Ishida et al., 2013). These findings offer one possible explanation for interindividual 
variation of bisoprolol levels, but future clinical studies investigating differences in drug 
bioavailability are required. Lastly, dialysis plays a very minor role in the clearance of 
carvedilol for ESRD patients whereas hepatic metabolism accounts for more than 98% of 
carvedilol disposition (Auro Pharma Inc., 2013). In particular, the diversity of genetic 
polymorphisms for the enzymes responsible for aromatic ring oxidation (CYP2D6 and 
CYP2C9) and glucuronidation (UGT2B7) have been shown to be important factors in the 
interindividual pharmacokinetic variability of carvedilol (Takekuma et al., 2007; Pan et 
al., 2016).  
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As important as dialytic clearance may be, non-dialytic mechanisms for clearance 
(e.g. hepatic or biliary excretion) still have a large role in dictating drug elimination 
during hemodialysis. In particular, almost all of carvedilol clearance was a result of non-
dialytic pathways. Metoprolol had a considerably higher total clearance as compared to 
all other beta blockers, most likely explained by combinations from both high hepatic 
metabolism and high dialytic clearance. Atenolol and bisoprolol required the largest post-
dialysis dose at nearly 23% (11 mg) and 40 % (2 mg) of their initial prescribed dose. For 
healthcare professionals determining the supplemental dose required to maintain patients 
within a therapeutic window, both dialytic and non-dialytic means of elimination must be 
considered. However, regulatory agencies should consider invoking specifications for 
highly dialyzable drugs to be taken only after dialysis in order to overcome the need for 
supplemental doses. These additional pharmacokinetic parameters that we examined have 
never been incorporated in previous dialyzability studies. Nonetheless, other groups 
investigating drug dialyzability can implement these equations to determine clinically-
relevant supplemental information. 
4.1.2 Retrospective Cohort Study 
A published study by Weir et al. (2015) has demonstrated the impact that drug 
dialyzability can have on clinical outcomes. Atenolol, metoprolol, and acebutolol were 
classified as “high dialyzability” beta blockers, while bisoprolol and propranolol were 
categorized as “low dialyzability” drugs. Hemodialysis patients prescribed highly 
dialyzed beta blockers exhibited a significantly increased risk for all-cause mortality and 
ventricular arrhythmia. Conversely, patients not requiring dialysis demonstrated no 
difference in risk for adverse clinical outcomes between dialyzability groups, as 
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expected. These findings strengthen the idea that beta blocker dialyzability should be 
considered when constructing future treatment plans. One limitation described by Weir et 
al. (2015) was that classification of dialyzability was based on either data from 
conventional dialysis membranes or solely on the physicochemical characteristics of the 
drugs. Indeed, results from our dialyzability study have since recognized that bisoprolol 
is actually moderately dialyzed, although it has been previously classified as non-
dialyzed (Table 1.3). In addition, patients administered carvedilol were omitted from the 
study due to its limited indications required for prescription in Ontario. Our current data 
creation plan comparing dialysis patients on carvedilol with those on metoprolol has 
since been submitted and approved by programmers, and is currently in queue for data 
analysis (Appendix G). The study objectives and design have been further described in 
Appendix F. It is unfortunate that a large delay in programming has made this data 
unavailable for incorporation into this thesis. Although the programming has taken longer 
than expected, we also delayed the start of the retrospective cohort study until all patient 
data from the dialyzability study was complete. We felt this was important since our 
findings in terms of dialyzability were essential in the data creation plan of the 
retrospective study.  
 
4.2 Research Significance 
Despite one study having previously shown that bisoprolol is removed during 
hemodialysis (Kanegae et al., 1999), it is still widely assumed that this beta blocker is 
minimally dialyzed. The findings from this clinical pharmacokinetic study demonstrate 
conclusively that bisoprolol should be re-categorized as having moderate dialyzability. 
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Although estimations of drug dialyzability can be made based on physicochemical 
properties, this unexpected discovery highlights the importance of conducting formal, 
experimental studies to definitively characterize drug dialyzability. CKD patients of all 
stages, with and without dialysis, must be better represented in the drug discovery 
process in order to optimize pharmacotherapy in this growing population. This has been 
acknowledged thus far by the FDA through the implementation of the 1998 FDA Renal 
Guidance and the current 2010 draft guidance that is pending implementation.  A recent 
survey conducted by Matzke et al. (2015) illustrates the positive impact on drug 
development created by the 1998 Renal Guidance. From 1999–2010, 71.6% of new 
investigational drugs conducted appropriate renal studies—a significant improvement 
from 51.6% in the two year span of 1996–1997 (Matzke et al., 2015). As the 1998 Renal 
Guidance did not emphasize renal studies for non-renally cleared drugs, the involvement 
of CKD patients were more likely observed in drugs characterized by renal excretion 
(89.6%) as compared with drugs that primarily display non-renal elimination (65.8%) 
(Matzke et al., 2015). Nearly 50% of NCEs with low renal clearance exhibited substantial 
pharmacokinetic changes. However, only one-third of those NCEs resulted in dosage 
recommendations and proper labeling. With greater emphasis in the 2010 draft guidance 
to complete renal and dialyzability studies in drugs with non-renal clearance, these results 
provide an encouraging outlook for future NCEs to standardize the incorporation of CKD 
patients in pharmacokinetic studies. In turn, accurate clinical information to describe 
which drugs require a supplemental dose can be determined, and recommendations can 
be made on preferred medication choices in hemodialysis patients for drugs in the same 
class.  
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Current clinical practice guidelines outlined by the National Kidney Foundation 
make no recommendations on which beta blocker should be prescribed to CKD and 
dialysis patients. Beta blockers have become a cornerstone treatment to battle 
cardiovascular disease due to their widespread applicability—from treating heart failure, 
to post myocardial infarctions, to angina (Kidney Disease Outcomes Quality Initiative, 
2004). The dialyzability of beta blockers found in our study can be implemented in future 
clinical practice guidelines and disseminated to healthcare professionals in order to help 
their drug selection process. One of the current recommendations by the National Kidney 
Foundation is to choose a simplified antihypertensive regimen with only a single daily 
dose requirement if possible (Kidney Disease Outcomes Quality Initiative, 2004). We 
now know that atenolol, bisoprolol, and metoprolol are all cleared during hemodialysis 
which indicates that patients may require a post-dialysis dose for their therapy to 
maintain levels required for efficacy. Conversely, carvedilol removal by dialysis is 
negligible. Due to renal excretion accounting for less than 2% of its elimination, plasma 
levels of carvedilol do not accumulate in any form of renal impairment (Deetjen et al., 
1995). These combined findings suggest that no dosage adjustments are required for 
carvedilol when patients progress from normal to reduced kidney function, even if renal 
replacement therapy is necessary (Miki et al., 1991; Gehr et al., 1999). Hence, the 
preferential selection of carvedilol over other beta blockers should be considered. 
In agreement, the strongest evidence in support of administering carvedilol as 
opposed to other beta blockers is due its proven efficacy in ESRD patients. Carvedilol is 
the only beta blocker and one of the only antihypertensive drugs that has been tested in 
prospective randomized clinical trials in dialysis patients. Cice et al. (2001) demonstrated 
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that for hemodialysis patients with dilated cardiomyopathy, a year-long administration of 
carvedilol reduces left ventricular volumes and improves overall cardiac function. This 
cohort of patients was subsequently followed for another 12 months to assess the effect of 
carvedilol on mortality and morbidity (Cice et al., 2003). When compared to placebo-
controlled patients, carvedilol significantly reduced all-cause mortality, cardiovascular 
mortality, and all-cause hospitalizations. Fatal myocardial infarctions and strokes—two 
main causes for cardiovascular death in ESRD patients (Saran et al., 2016)—were also 
considerably reduced in carvedilol-treated subjects.  
Although carvedilol is typically reserved for patients with symptomatic heart 
failure, it may be worth considering expanding the application of carvedilol in dialysis 
patients. Based on its ideal pharmacokinetic qualities in CKD patients and previous 
clinical trials indicating its strength to improve patient morbidity, we are hopeful that the 
administration of carvedilol will become more liberal.  
4.3 Limitations and Future Directions 
When conducting pharmacokinetic studies to categorize drug dialyzability, the 
recovery clearance method is widely accepted as the gold-standard approach. One 
limitation for using this method is the requirement for a sensitive technique when 
measuring very low drug concentrations in large volumes of dialysate. Despite us 
concentrating samples 100-fold and our UPLC-MS providing accurate, sensitive 
detection of small molecules, some dialysate samples containing carvedilol were below 
our LLOQ. However, negligible dialytic clearance of the beta blocker may have resulted 
in samples having virtually no carvedilol for detection. 
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Subjects enrolled in our study had dialysis durations varying from 3 to 4 hours. 
Patient variability in dialysis time result in differences in how much drug is remaining at 
the end of dialysis. However, the dialytic clearance values are not affected by shorter or 
longer dialysis durations since the recovery clearance equation (Equation 2) takes the 
ratio of amount dialyzed over total drug exposure. Regarding study design, a single oral 
dose prescription as used in our study may not produce pharmacokinetic parameters 
reflective of patients on long-term beta blocker therapy. For instance, dialytic clearance is 
dependent on dialysis prescription factors including blood flow rate, dialysate flow rate, 
and ultrafiltration rate—all of which can vary from one dialysis session to another. 
Despite this, the overall categorization of a drug’s dialyzability is not expected to change 
significantly. One proposed future study can examine the dialytic clearance of beta 
blockers for dialysis patients at steady state. Additionally, plasma concentration of beta 
blockers at steady state should be compared between normal renal function and chronic 
hemodialysis patients. If drug dialyzability is an important determinant of therapeutic 
efficacy, we expect that highly dialyzed drugs would exhibit a substantially lower steady 
state concentration in subjects on dialysis while poorly dialyzed drugs will show no 
difference in plasma levels.  
Another caveat in our study was the use of literature values to determine 
additional pharmacokinetic parameters (VD, FU, and kE). The studies used had small 
sample sizes which may produce values that are not representative for all CKD patients. 
In addition, the supplemental dose calculated for each beta blocker did not account for 
post-dialysis rebound of the drugs. Future study designs will attempt to include more 
sample collection at time points after the dialysis session to characterize any potential 
69 
 
drug distribution out of tissue. Nonetheless, these equations still provide the framework 
to determine clinically-relevant parameters for any subsequent dialyzability studies. 
The unexpected result of bisoprolol having moderate dialyzability prompted us to 
review other drugs prescribed to subjects during the duration of the study. We compiled a 
list of different drug classes of interest including narcotics (morphine and codeine), 
vitamin D supplements (alfacalcidol and calcitriol), cardiovascular medications (ACE 
inhibitors, ARBs, CCBs and statins), antipsychotics (lorazepam, diazepam, gabapentin, 
etc.), anticoagulants, and proton pump inhibitors (lansoprazole and rabeprazole). 
Morphine, codeine, lansoprazole, and warfarin were detected in patient dialysate samples 
despite the latter 3 drugs being listed as not dialyzble (Figure 4.1) (Baillie and Mason, 
2013). This finding confirms the notion that studies involving conventional hemodialysis 
have become obsolete and drug dialyzability must be further investigated to optimize 
pharmacotherapy in ESRD patients. Looking forward, similar dialyzability studies should 
be conducted for other classes of cardiovascular medications (ACE inhibitors, ARBs, 
CCBs and anticoagulants) in hopes of improving the overall management of cardiac 
disease in dialysis patients. Results from both present and future investigations will be 
disseminated to practitioners and regulatory agencies for knowledge translation into 
clinical practice guidelines. 
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Figure 4.1. Select drugs of interest detected in subject dialysate samples. 
A list of drugs of interest was created after reviewing the prescription record of subjects 
during the study period. Morphine (A), codeine (B), lansoprazole (C), and warfarin (D) 
were detected in patient dialysate samples using ultra-performance liquid 
chromatography coupled to quadrupole time-of-flight mass spectrometry (UPLC-
QToFMS).  
  
(A) 
(B) 
(D) 
(E) 
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4.4 Conclusions 
In much of recent literature, adequacy of dialysis for ESRD patients has been 
erroneously assumed to be synonymous with adequacy of patient care (National Kidney 
Foundation, 2015). This concept and approach to healthcare is inaccurate. The overall 
purpose for renal replacement therapy is to improve the quality of life and prognosis for a 
vulnerable, globally-growing population. However, many aspects of the treatment plan 
for ESRD patients are established prior to the renal replacement strategy and are 
independent or only partially-dependent on dialysis itself. For example, the dosage 
regimen for drug therapy is often devised in earlier stages of CKD but become 
extensively intertwined with the daily life of dialysis patients to combat cardiovascular 
complications and other comorbidities. As such, the importance of dialyzability research 
has been identified by an international guideline committee for renal disease, Kidney 
Disease | Improving Global Outcomes (KDIGO) (Atkinson and Umans, 2010; Dager, 
2010). When drugs are approved for use in the general population, they must undergo 
extensive pharmacokinetic evaluation for determination of renal clearance among other 
parameters. Despite the widespread use of cardiovascular medications in patients 
receiving hemodialysis and the clear difference between dialytic and renal excretion, 
there still remains a paucity of data describing drug elimination during dialysis. In this 
study, we were able to definitively categorize the four most commonly prescribed beta 
blockers in Ontario into high (atenolol, metoprolol), moderate (bisoprolol) and low 
(carvedilol) dialyzability drug groups. Clinicians and scientists are encouraged to 
continue conducting pharmacokinetic studies to characterize drug dialyzability and 
provide more evidence on the necessity of including dialysis patients in drug 
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development. When considering study design for future dialyzability studies, it would be 
ideal to conduct studies in both single-dose and steady-state dosing conditions, use the 
superior recovery clearance method, and confirm that drug concentrations remain in the 
therapeutic window following dialysis to ensure efficacy. The clear implications that drug 
dialyzability has for the efficacy of pharmacotherapy will hopefully improve quality of 
care and prognosis for all patients receiving chronic hemodialysis. 
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Appendix C: Supplementary Information 
 
Supplementary Table C1. Dialyzability of angiotensin converting enzyme (ACE) inhibitors. 
ACE Inhibitor 
Molecular 
Weight 
(Daltons) 
Protein 
binding 
(%) 
Volume of 
distribution 
(L/kg) 
Dialyzability Data 
Specified 
Dialyzability Testing 
Conditions* 
Clearance 
during 
hemodialysis 
(ml/min)  
Reference 
Fosinoprilat 435 99 
“very 
small” 
Recovery method 
Single dose 
Dialyzer: cellulose  
QD: 550 ml/min 
QB: 250 ml/min 
4 
(Gehr et al., 
1993) 
Ramiprilat 388 56 1.2 
A-V Difference method 
Multiple doses 
Dialyzer: cellulose  
QD: 500 ml/min 
QB: 250-300 ml/min 
21 
(Fillastre et 
al., 1996) A-V Difference method 
Single dose 
Dialyzer: cellulose  
QD: 500 ml/min 
QB: 250-300 ml/min 
32 
Enalaprilat 348 50 1.7 
A-V Difference method 
Multiple doses 
QB: 230 ml/min 
39 
(Kelly et al., 
1988) 
A-V Difference method 
Single dose 
Dialyzer: cellulose 
QD: 500 ml/min 
QB: 300 ml/min 
68 
(Fruncillo et 
al., 1987) A-V Difference method 
Multiple doses 
Dialyzer: cellulose 
QD: 500 ml/min 
QB: 300 ml/min 
57 
Lisinopril 405 < 1 2.4  
A-V Difference method 
Multiple doses 
Dialyzer: ? 
QD: ? 
QB: 230 ml/min 
40 
(Kelly et al., 
1988) 
Perinoprilat 340 15 0.2 
A-V Difference method 
Single dose 
Dialyzer: polysulfone 
QD: 500 ml/min 
QB: 300 ml/min 
62 
(Guérin et 
al., 1993) A-V Difference method 
Multiple doses 
Dialyzer: polysulfone 
QD: 500 ml/min 
QB: 300 ml/min 
72 
A-V Difference method 
Single dose 
Dialyzer: cellulose 
triacetate 
QB: 200 ml/min 
66 
(Verpooten 
et al., 1991) 
A-V Difference method 
Multiple doses 
Dialyzer: polysulfone 
QD: ? 
QB: 200 ml/min 
108 
(Yamada et 
al., 2003) 
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Benazeprilat 396 95 0.1 No data No data - 
Quinaprilat 428 97 0.4  
A-V Difference method 
Multiple doses 
Dialyzer: polysulfone 
QD: ? 
QB: 200 ml/min 
52 
(Yamada et 
al., 2003) 
Trandolaprilat 402 75 0.3 No data No data - 
* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug 
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is 
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and 
venous (V) limbs of the dialysis machine and the blood flow rate.  
Abbreviations: QD, dialysate flow rate; QB, blood flow rate; UF, ultrafiltration rate. 
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Supplementary Table C2. Dialyzability of study angiotensin II receptor blockers (ARBs).  
ARB 
Molecular 
Weight 
(Daltons) 
Protein 
binding 
(%) 
Volume of 
distribution 
(L/kg) 
Dialyzability Data 
Specified 
Dialyzability Testing 
Conditions* 
Clearance 
during 
hemodialysis 
(ml/min)  
Reference 
Candesartan 440 99  0.13 
A-V Difference method  
Multiple doses 
Dialyzer: polysulfone 
QD: 500 ml/min 
QB: 400 ml/min 
1.5 
(Pfister et al., 
1999) 
Irbesartan  429 90 0.75 
A-V Difference method 
Multiple doses 
Dialyzer: ?  
QD: ? 
QB: ?  
“Not removed” 
(Sica et al., 
1997) 
Losartan  423 99 0.49 
A-V Difference method 
Single dose 
Dialyzer: polysulfone  
QD: 500 ml/min 
QB: 400 ml/min 
“Approximately 
zero” 
(Sica et al., 
2000) 
Olmesartan  447 99 0.24 
A-V Difference method 
Single dose 
Dialyzer: polysulfone  
QD: ?  
QB: ? 
“Not removed” 
(Tanaka et al., 
2009) 
Telmisartan  515 99  >7 
Recovery method 
Single dose 
Dialyzer: olysulfone 
QD: ? 
QB: ? 
“Very little 
removed” 
(Stangier et 
al., 2000) 
Valsartan 436 95 0.24 No data No data - 
* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug 
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is 
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and 
venous (V) limbs of the dialysis machine and the blood flow rate.  
Abbreviations: QD, dialysate flow rate; QB, blood flow rate. 
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Supplementary Table C3. Dialyzability of calcium channel blockers. 
Calcium 
Channel 
Blocker 
Molecular 
Weight 
(Daltons) 
Protein 
binding 
(%) 
Volume of 
distribution 
(L/kg) 
Dialyzability Data 
Specified Dialyzability 
Testing Conditions* 
Clearance 
during 
hemodialysis 
(ml/min)  
Reference 
Amlodipine 567.1 98 0.3 
One time concentration 
of dialysate 
Dialyzer: ? 
QD: ? 
QB: ? 
No clearance 
data, but 
concentration 
in dialysate 
very low  
(Kungys et 
al., 2003) 
Diltiazem 451 70-80 0.07-0.15 No Data No Data  - 
Felodipine 384.2 >99 0.15 
A-V Difference method 
Single oral dose 
followed by single IV 
dose 
Dialyzer: cellulose  
QD: 500 ml/min 
QB: 200 ml/min 
Negligible, but 
inactive 
metabolites 
with clearance 
of 8.4-13.8 
(Buur et 
al., 1991) 
Nicardipine 516 98 0.6-6.8 No Data No data - 
Nifedipine 346.3 88-95 0.75-1.5 
A-V Difference method 
Single dose 
Dialyzer: 1.2 m2 
cuprophane 
QD: 500 ml/min 
QB: 200 ml/min 
2.8 
(Martre et 
al., 1985) 
Verapamil 491.1 90 3.8-5 
A-V Difference method 
Single dose 
Dialyzer: cuprophane 
QD:  ? 
QB: 250-280 ml/min 
Negligible 
(Hanyok et 
al., 1988) 
Recovery method 
Multiple doses 
Dialyzer: cuprophane 
QD:  500 
QB: 200 ml/min 
Negligible 
(Shah and 
Winer, 
1985) 
* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug 
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is 
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and 
venous (V) limbs of the dialysis machine and the blood flow rate.  
Abbreviations: QD, dialysate flow rate; QB, blood flow rate, IV, intravenous. 
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Supplementary Table C4. Dialyzability of antiplatelet agents. 
Antiplatelet 
Agent 
Molecular 
Weight 
(Daltons) 
Protein 
binding 
(%) 
Volume of 
distribution 
(L/kg) 
Dialyzability Data 
Specified 
Dialyzability Testing 
Conditions* 
Clearance 
during 
hemodialysis 
(ml/min)  
Reference 
Acetylsalicylic 
Acid (Aspirin) 
180 99.5  0.15-0.20   
A-V Difference method 
Dialyzer: ? 
QD: ? 
QB: 200 ml/min 
86** 
(Jacobsen 
et al., 
1988) 
A-V Difference method 
Dialyzer: cuprophane  
QD: ? 
QB: 100 ml/min 
30-35** 
(Doolan et 
al., 1951) 
(Spritz et 
al., 1959) 
A-V Difference method 
Dialyzer: cuprophane  
QD: ? 
QB: 250 ml/min 
80** 
(Kallen et 
al., 1966) 
Dipyridamole 505 91-99 1.0-2.5 No Data No Data - 
Clopidogrel 321 98 - No Data No Data - 
Prasugrel 373 98  - No Data No Data - 
Sulfinpyrazone 404 98 0.35 
Single dose 
Dialyzer: cuprophane  
QD: ? 
QB: ? 
Negligible 
(Bern et 
al., 1980) 
Ticagrelor 340 >99.7 1.25 No Data No Data - 
Ticlopidine 264 98 - No Data No Data - 
* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug 
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is 
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and 
venous (V) limbs of the dialysis machine and the blood flow rate.  
** Data derived from overdose settings 
Abbreviations: QD, dialysate flow rate; QB, blood flow rate. 
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Supplementary Table C5. Dialyzability of anitcoagulants.  
Oral 
Anticoagulants 
Molecular 
Weight 
(Daltons) 
Protein 
binding 
(%) 
Volume of 
distribution 
(L/kg) 
Dialyzability Data 
Specified 
Dialyzability 
Testing 
Conditions* 
Clearance 
during 
hemodialysis 
(ml/min)  
Reference 
Warfarin 308 99 0.14 
A-V Difference 
method  
Multiple 
Dialyzer: 
sulphonated 
cellulose acetate 
QD: 500 ml/min 
QB: 300 ml/min 
31% drop in 
warfarin 
concentratio
n during 
dialysis 
(Ifudu and 
Dulin, 1993) 
Acenocoumarol 343 98.7 0.18  No Data No Data - 
Apixaban 459 >90%  0.3  No Data 18** - 
Dabigatran 627.7 35 0.85-1.0 
A-V Difference 
method 
Steady State 
Dialyzer: “high-
flux”  
QD: ?  
QB: 350 mL/min 
10 ng/mL 
per hour 
(Chang et al., 
2013) 
A-V Difference 
method 
Multiple doses 
Dialyzer: Polyflux 
PF  
QD: 700 mL/min 
QB: 200 mL/min 
161 
(Khadzhynov 
et al., 2013) A-V Difference 
method 
Multiple Dose 
Dialyzer: Polyflux 
PF  
QD: 700 mL/min 
QB: 400 mL/min 
241 
Rivaroxaban 436 92-95 0.7 
A-V Difference 
method 
Multiple doses 
Dialyzer: 
polysulfone 
QD: 500 mL/min 
QB: 400 mL/min 
0  
(De Vriese et 
al., 2015) 
Low Molecular Weight Heparin 
Enoxaparin 1117 80 0.07 No Data No Data - 
Dalteparin 6000 - 0.04 No Data No Data - 
Nadroparin 4300 - 0.05  No Data No Data - 
Injectable Direct Thrombin Inhibitors 
Desirudin 6964 - 0.26 No Data No Data - 
Bivalirudin 2180 - 0.2 
Steady State 
Dialyzer: ? 
QD: ? 
QB: ? 
72.8§ 
(Robson, 
2000) 
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Argatroban 509 54 0.17 
Recovery method 
Multiple doses 
Dialyzer: Cellulose 
Triacetate 
QD: ? 
QB: ? 
49§ 
(Murray et al., 
2004) 
Injectable Factor Xa Inhibitors 
Fondaparinux 1730 94 0.1 – 0.16 
Population 
pharmacokinetics 
model 
Multiple doses 
Dialyzer: High flux 
QD: 500 mL/min 
QB: 388 mL/min 
9.8 
(Kalicki et al., 
2007) 
Danaparoid ~6000 - 0.1 No Data No Data - 
* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug 
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is 
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and 
venous (V) limbs of the dialysis machine and the blood flow rate. 
** From Product Monograph. 
§ Normalized to 70 kg body weight. 
Abbreviations: QD, dialysate flow rate; QB, blood flow rate 
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Supplementary Table C6. Dialyzability of cholesterol-lowering medications. 
Cholesterol 
Lowering 
Drugs 
Molecular 
Weight 
(Daltons) 
Protein 
binding 
(%) 
Volume of 
distribution 
(L/kg) 
Dialyzability Data 
Specified Dialyzability 
Testing Conditions* 
Clearance 
during 
hemodialysis 
(ml/min)  
Reference 
Atorvastatin 558 ≥98 381 
Single oral dose 
Dialyzer: ? 
QD: ? 
QB: ? 
Negligible 
(Lins et al., 
2003) 
Rosuvastatin 482 88 134  
A-V Difference method 
Steady State 
Dialyzer:  ? 
QD: ? 
QB: ?  
 
34.8 for 
Rosuvastatin 
 
<42 for 
metabolites 
 
(Birmingha
m et al., 
2013) 
Simvastatin 419 95 -- No Data No Data  - 
Pravastatin  425 50 56 
A-V Difference method 
Multiple doses 
Dialyzer: Cellulose acetate  
QD: ? 
QB: 200-250 mL/min 
38-55  
(Gehr et al., 
1997) 
Recovery method 
Multiple doses 
Dialyzer: Cellulose acetate  
QD: ? 
QB: 200-250 mL/min 
49-81  
Fluvastatin  411 98 - 
A-V Difference method 
Dialyzer: pulysulfone 
QD: 500 mL/min 
QB: 180-300 mL/min 
Negligible  
(Ichimaru et 
al., 2004) 
Recovery method 
Dialyzer: ? 
QD: ? 
QB: ? 
Negligible 
 
(Appel‐
Dingemanse 
et al., 2002) 
Lovastatin 405 >95 - No data No data - 
Ezetimibe 409 >90 - No Data No data - 
* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug 
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is 
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and 
venous (V) limbs of the dialysis machine and the blood flow rate.  
Abbreviations: QD, dialysate flow rate; QB, blood flow rate. 
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Appendix D: Screening Criteria for Subject Enrolment 
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Appendix E: Letter of Information 
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Appendix F: Effect of Dialyzability on Clinical Outcomes 
Aim: Evaluate the effect of beta blocker dialyzability on risk for all-cause mortality 
and cardiovascular outcomes.  
After categorizing beta blockers into their dialyzability group, a propensity-
matched, population-based retrospective cohort study was designed using the linked 
health administrative databases of Ontario, Canada (Appendix F). To assess the effect of 
dialyzability on clinical adverse outcomes, chronic hemodialysis patients on a poorly 
dialyzed beta blocker (carvedilol) were compared to those on a highly dialyzed beta 
blocker (metoprolol). 
A recent study by Weir et al. (2015) has shown that elderly hemodialysis patients 
prescribed highly dialyzed beta blockers had a significant 1.4 fold increase in the risk for 
all-cause mortality as compared to patients on poorly dialyzed beta blockers. One 
criticism expressed for this previous study was the omission of carvedilol-treated patients 
(Shroff and Herzog, 2015). Carvedilol is the only beta blocker with a prospective clinical 
trial to prove its efficacy in subjects receiving dialysis (Cice et al., 2003). Consequently, 
the data creation plan for our study compares hemodialysis patients on carvedilol to those 
on metoprolol. Due to the low dialyzability of carvedilol, we expect that patients 
receiving this drug will have a comparatively better survival benefit and a decreased risk 
for cardiovascular outcomes.  
 
Methods 
 
Study design 
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A provincial-wide retrospective matched cohort study was conducted using health 
administrative data from April 1, 2002 to September 30, 2014 on all chronic 
hemodialysis patients who were older than 66 years. One cohort of subjects included only 
those with evidence of continuous carvedilol use (low dialyzability group), and the other 
included those with only continuous use of metoprolol (high dialyzability group). 
Subjects were propensity matched between the two dialyzability cohorts and compared 
for their risk of all-cause mortality and adverse cardiovascular outcomes using odds 
ratios. We collected and analyzed all exposure, outcome and covariate data according to a 
predefined protocol. The study was approved by the institutional review board at 
Sunnybrook Health Sciences Centre, Toronto, Canada, and its design and reporting 
follow the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement guidelines (von Elm et al., 2008).  
Setting 
Ontario is the most populated province in Canada with nearly 13 million residents 
in 2011—1.9 million of whom were 65 years of age or older (Statistics Canada, 2012). 
The Ontario Health Insurance Plan (OHIP) provides all residents of Ontario with 
universal access to physician and hospital services. Additionally, the Ontario Drugs 
Benefit (ODB) program allows access for those who are 65 years and older to universal 
coverage for many prescription medications. The single health insurance payer in Ontario 
and an emigration rate of less than one percent per year produces a database of health 
administrative information that is both comprehensive and stable (Ontario Ministry of 
Finance, 2016). 
Sources of Administrative Data 
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We used Ontario’s health administrative data housed at the Institute of Clinical 
Evaluative Sciences (ICES) to assemble a cohort of patients receiving chronic 
hemodialysis and determined the impact of dialyzability on mortality and cardiovascular 
outcomes. We identified patients, exposures, outcomes and covariates using four linked 
datasets: (1) Ontario Drug Benefits (ODB) Database. Information on outpatient 
medications in the ODB formulary was used to ascertain drug-related baseline 
characteristics and beta blocker exposure, a covariate in our regression model. (2) 
Canadian Institute of Health Information (CIHI) Discharge Abstract Database (DAD). 
This database was used to identify patient baseline characteristics, hospital admission for 
cardiovascular complications, and potential confounding diagnoses. The causes for 
hospitalizations were determined based on the codes found in the ninth and tenth editions 
of the International Classification of Disease (ICD-9 and ICD-10). The accuracy of the 
codes in these databases has been assessed for many diagnoses (Jong et al., 2003; 
Juurlink et al., 2006). (3) Ontario Health Insurance Plan (OHIP) Claims History 
Database. Most physicians submit billing claims with diagnoses codes that contain 
information on inpatient, outpatient and laboratory services. This OHIP database 
ascertained cardiovascular procedures and confounding variables to be included in our 
regression models. (4) Registered Persons Database (RPDB). The RPDB captures 
information regarding sex, date of birth, postal code and vital status. This database was 
used to confirm patient mortality. Relative to the CIHI-DAD, the RPDB has a sensitivity 
of 94% and a positive predictive value of 100% for flagging in-hospital mortality (Jha et 
al., 1996). 
Study Population and Cohorts 
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In order to ensure that the cohorts of patients were administered one of the two 
beta blockers during the entirety of their hemodialysis treatment, physician billing 
records from April 1, 2002 to March 31, 2015 were first used to determine all patients 
who were treated with long-term hemodialysis. The index date used to identify eligible 
patients was the date of the first prescription for carvedilol or metoprolol.  Subject 
enrollment was restricted to those older than 66 years old. This minimal age limitation 
was implemented to guarantee at least 1 year of drug use data since Ontario citizens over 
the age of 65 years receive universal coverage for prescription medications. Following 
the age restriction, patients were further filtered by excluding those with greater than one 
beta blocker prescription and those who did not fill a prescription for one of the two study 
beta blockers. To identify beta blocker initiation that occurred while receiving 
hemodialysis, patient prescriptions that were not preceded within 30 days by a long-term 
hemodialysis code (H540, H740, G325, G326, G860, G862, G863 and G866) were 
excluded. Furthermore, patients were excluded if they filled any beta blocker prescription 
within 120 days of their first filled prescription while on hemodialysis. This ensured that 
enrolled patients were new users of the beta blockers.  
Beta blocker dialyzability was the main exposure. Based on findings from the 
pharmacokinetic, 4-way crossover study (Figure 3.3), patients prescribed carvedilol were 
categorized into the “low dialyzability” exposure group. Conversely, those prescribed 
metoprolol were classified as the “high dialyzability” control group. 
Propensity Score Computation and Matching 
For the hemodialysis cohort, prevalence of baseline characteristics between the 
high and low dialyzability patient groups was compared. Following this comparison, 
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carvedilol patients were matched to those on metoprolol in a one-to-two ratio based on 
age (± 2 years), sex, and propensity score (±0.2 SD). Patients were matched without 
replacement such that unexposed patients who have been matched can no longer serve as 
a candidate for comparison with another patient. Propensity score analyses mitigate the 
effects of imbalances in baseline characteristics on estimates of risk (Rosenbaum and 
Rubin, 1983). Propensity scores were computed using a logistic regression model in 
which metoprolol use was the dependent variable. Independent variables for the study 
included age, year of index, sex, Charlson and John Hopkins comorbidity scores, 
comorbid conditions (abdominal aortic aneurysm, coronary artery disease, heart failure, 
peripheral vascular disease, and stroke), general measures of comorbidity (duration of 
dialysis and number of unique prescriptions within the last year), and concomitant 
medications (ACE inhibitors, alpha blockers, ARBs, CCBs, diabetes drugs, digoxin, and 
nitrates).  
Outcome Measures 
The primary outcome was all cause mortality identified using the RPDB. The 
secondary outcome is a composite of myocardial infarction, heart failure or ventricular 
arrhythmia as identified by their corresponding hospitalization outcome codes. All 
outcomes were specified prior to data analysis and assessed up to 180 days after the index 
beta blocker prescription. This period of follow-up was chosen on the basis of the 
findings that the median (interquartile range) duration of continuous use was 471 (85–
646) days for high dialyzability beta blockers and 508 (78–752) days for low 
dialyzability beta blockers. The shorter observation period of 180 days allows for a 
decreased likelihood of dropout or crossover between exposure groups.   
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Statistical Methods 
The first analysis conducted in this study was to determine imbalances in baseline 
characteristics between exposure groups using standardized differences. This metric 
describes differences between group means relative to their pooled standard deviation. 
An absolute standardized difference of a covariate that is less than 10% is 
inconsequential, and a 0% difference indicates no imbalance between the two exposure 
groups for that covariate. Standardized differences that are greater than 10% describe 
significant imbalances between the cohorts in question (Mamdani et al., 2005; Austin, 
2009).  After propensity matching patients, comparisons between the two dialyzability 
groups were conducted. Conditional logistic regression analyses were used to estimate 
odds ratios and 95% confidence intervals (CIs). Odds ratios were subsequently 
interpreted as relative risks (RRs), which is reasonable given the low incidence of 
outcomes. All analyses were completed with SAS software, version 9.2 (SAS Institute 
Inc., Cary, NC). 
Results 
Upon completion of the clinical pharmacokinetic study, we were able to 
decisively conclude that dialysis has a negligible impact on the clearance of carvedilol, 
while metoprolol is highly dialyzed. These categorizations of beta blocker dialyzability 
were translated into our data creation plan developed for a provincial-wide retrospective 
cohort study. Unfortunately, unforeseen delays in programming at the Institute of Clinical 
Evaluative Sciences (ICES) have hindered completion of this study. Our study design has 
been approved and is currently in sequence for data analysis. Hemodialysis patients in the 
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high dialyzability group (metoprolol) are still expected to exhibit an augmented risk for 
mortality and adverse cardiovascular outcomes as compared with those in the low 
dialyzability group (carvedilol).  
  
118 
 
Appendix G: Data Creation Plan – Beta blocker dialyzability: 
Carvedilol 
 
 Project Initiation 
 This Section must be Completed Prior to Project Dataset(s) Creation 
Project Title: Beta blocker dialyzability: Carvedilol 
Project TRIM number: 2016 0906 194 000  
Research Program: KDT 
Site: ICES Western 
Project Objectives: Insert Project Objectives as listed in the approved ICES Project 
PIA 
To determine whether outcomes are better with carvedilol (non-
dialyzable) compared to metoprolol (highly dialyzable) in 
patients on hemodialysis.   
ICES Project PIA 
Initial Approval Date: 
The ICES Employee or agent who is responsible for creating the 
Project Dataset(s) is responsible for ensuring there is an 
approved ICES Project PIA and verifying the date of approval 
prior to creating the Project Dataset(s) 
2016-Mar-10  
Principal Investigator 
(PI): 
Matthew Weir 
Check the applicable 
box if the PI is an ICES 
Student/Trainee 
☐ ICES Student ☐ ICES Fellow ☐ ICES Post-
Doctoral Trainee     ☐ Visiting Scholar 
Responsible ICES 
Scientist: 
Name the Responsible ICES Scientist if the PI is not a Full 
Status ICES Scientist 
Amit Garg 
Project Team 
Member(s) Responsible 
for Project Dataset 
Creation and/or 
Statistical Analysis and 
date joined (list all): 
All person(s) (ICES Analyst, Appointed Analyst, Analytic 
Epidemiologist, PI, and/or Student) responsible for creating the 
Project Dataset(s) and/or statistical analysis on the Research 
Analytics Environment (RAE) and the date they joined the 
project must be recorded 
Stephanie Dixon, 519-685-8500 ext 55979, 
stephanie.dixon@ices.on.ca  
2016-Jan-22 
Other ICES Project 
Team Members and 
date joined (list all): 
All other Research Project Team Members (e.g., Research 
Administrative Assistants, Research Assistants, Project 
Managers, Epidemiologists) and the date they joined the project 
must be recorded 
Racquel Jandoc, 519-685-8500 ext 77849, 
racquel.jandoc@ices.on.ca 
Danielle Nash, 519-685-8500 ext 55980,  
danielle.nash@ices.on.ca  
2016-Jan-22 
Confirmation that DCP The following individuals must confirm that the ICES Data 
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 Project Initiation 
 This Section must be Completed Prior to Project Dataset(s) Creation 
is consistent with 
Project Objectives: 
provided for in this DCP is relevant (e.g., with respect to cohort, 
timeframe, and variables) and required to achieve the Project 
Objectives stated in the ICES Project PIA prior to initial Project 
Dataset creation: 1) PI; 2) Responsible ICES Scientist if the PI 
is not a Full Status ICES Scientist, or a second ICES Scientist or 
the Scientific Program Lead if the PI is creating both the DCP 
and the Project Dataset[s]; 3) ICES Research Practice Staff 
creating the DCP; and 4) ICES Analytic Staff (ICES Employee 
or agent responsible for creating the Project Dataset[s]). This 
may be delegated either verbally or via e-mail. 
Principal Investigator: Matthew Weir ☒ 2015-Feb-05 
Responsible ICES Scientist or Second 
ICES Scientist/Lead: Amit Garg ☒ 2016-Apr-20 
ICES Research Practice Staff Creating 
the DCP: Danielle Nash ☒ 2015-Feb-05 
ICES Analytic Staff: Stephanie Dixon ☒ 2015-Feb-05 
Designated ICES 
Research Practice Staff 
accountable for Project 
Documentation: 
The person named (ICES staff) is accountable for ensuring that 
the approved ICES Project PIA, ICES Project PIA Amendments, 
and DCP are saved on the T Drive, ensuring ICES Project PIA 
Amendments are submitted as required, ensuring DCP 
Amendments are documented, and sharing the final DCP with 
the PI/Responsible ICES Scientist at project completion 
Racquel Jandoc 
DCP Creation Date and 
Author: 
Date DCP was finalized 
prior to Project Dataset(s) 
creation 
Name of person who created the 
DCP 
Date  Name  
2016-Apr-20 Matthew Weir  
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 ICES Data 
 This Section must be Completed Prior to Project Dataset(s) Creation 
The ICES Employee or agent who is responsible for 
creating the Project Dataset(s) must ensure that this list 
includes only data listed in the ICES Project PIA 
Changes to this list after initial ICES Project PIA 
approval require an ICES Project PIA Amendment 
Mandatory for all datasets that 
are available by individual year 
General Use Datasets – Health Services Years (where applicable) 
CIHI DAD 1997-2015 
CIHI SDS 1997-2015 
NACRS 1997-2015 
ODB 2001-2015 
OHIP 1997-2015 
See list  
General Use Datasets – Care Providers  
IPDB 1997-2013 
See list  
General Use Datasets – Population  
RPDB 1997-2015 
See list  
General Use Datasets – Coding/Geography  
See list  
See list  
General Use Datasets - Facilities  
See list  
General Use Datasets - Other  
See list  
See list  
Controlled Use Datasets  
See list  
See list  
Other Datasets  
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 Project Amendments and Reconciliation 
ICES Project PIA 
Amendment History 
(add additional rows as 
needed): 
Privacy 
approval 
date 
Person who 
submitted 
amendment 
Note that any changes to the list of 
ICES Data or Project Objectives 
require an ICES Project PIA 
Amendment 
Date Name Amendment 
yyyy-mon-
dd 
  
DCP Amendment 
History (add additional 
rows as needed): Date DCP 
amended 
Person who 
made the DCP 
amendment 
Note that any DCP amendments 
involving changes to the list of ICES 
Data or Project Objectives require 
an ICES Project PIA Amendment 
Date Name Amendment 
yyyy-mon-
dd 
  
Date Programs/DCP 
reconciled 
The person(s) creating the dataset and/or analyzing the data are 
responsible for ensuring that the  final DCP reflects the final 
program(s) when the project is completed 
yyyy-mon-dd 
 
 
 Project Cohort 
Study Design ☐ Cohort study  ☒ Matched cohort study 
 ☐ Case-control study 
☐ Cross-sectional study ☐ Other (specify):   
Index Event / 
Inclusion Criteria 
Inclusion criteria:  
1. Patients with evidence of at least 1 chronic hemodialysis 
code (Appendix B) between April 1, 2002 to September 
30, 2014, and 
2. First evidence of one study drug during the same time 
period 
 
Index date:  
First prescription for a study drug (Appendix A, DCLASS= 
“S_BBC”, “S_BBM”) 
Estimated Size of 
Cohort  
(if known) 
Carvedilol (DCLASS= “S_BBC”) = 600 
Metoprolol (DCLASS= “S_BBM”) = 1200 (2:1 matched to 
carvedilol patients) 
Exclusions (in order) Step Description 
1 Data cleaning:  
a) Patients with missing or invalid IKN 
b) Patients with missing or invalid age or sex data 
c) Death on or before index date 
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 Project Cohort 
d) Non-Ontario residents (individuals without an 
RPDB variable “prdcddablk” beginning with “35”) 
2 Patients ≤66 years old as of index date 
3 Evidence of a hospital discharge or an emergency 
department visit on or within ≤2 days prior to index date 
(including index date)  
4 No evidence of a chronic hemodialysis code in the 30 
days prior to and including index date (this is intended to 
eliminate patient who started beta blockers prior to 
starting hemodialysis) (Appendix B) 
5 Evidence of any study beta blocker prescription in the 120 
days prior to index date (not including index date)  
(Appendix A, DCLASS= “S_BBC”, “S_BBM”) 
6 Exclude patients with >1 of any beta blocker prescription 
on the index date (Appendix A, DCLASS= “S_BBC”, 
“S_BBM”, “NS_BBL”)   
 
 
 Project Time Frame Definitions 
 
 
Accrual Start/End 
Dates 
April 1, 2002 to September 30, 2014 
Max Follow-up Date March 31, 2015 
When does observation 
window terminate? 
First instance of any of the following events: 
1. Death 
2. 180 days of follow-up 
3. March 31, 2015 
Lookback Window(s) Do not include index date in lookback  
 Comorbid conditions: 2 years 
 Health care access: 1 year 
 Baseline medications: 1 year 
 
 
 Variable Definitions (add additional rows as needed) 
Main Exposure or Risk 
Factor 
Beta blocker dialyzability 
 Exposed group: patients prescribed carvedilol (low 
dialyzability) (Appendix A, DCLASS = “S_BBC”)  
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 Variable Definitions (add additional rows as needed) 
 Control group: patients prescribed metoprolol (high 
dialyzability) (Appendix A, DCLASS = “S_BBM”) 
Primary Outcome 
Definition 
Look forward 180 days following index date (not including 
index date) for:  
 All-cause mortality (Appendix C)  
Secondary Outcome 
Definition(s) 
Look forward 180 days following index date (not including 
index date) for:  
 Myocardial infarction 
 Heart failure  
 Ventricular arrhythmia  
 
See Appendix C for outcome codes  
Baseline Characteristics See Appendix E for baseline codes and Appendix F for full 
baseline table 
Other Variables  
 
 
 Analysis Plan and Dummy Tables (expand/modify as needed) 
Descriptive Tables (insert or append dummy tables), e.g.: 
 Table 1. Baseline characteristics according to primary/secondary exposure 
 Table 2. Outcomes according to primary/secondary exposure 
 Table 3. Covariates (baseline characteristics) according to outcomes  
Statistical Model(s) 
 Type of model  
 Primary independent 
variable 
 
 Dependent variable  
 Covariates  
Sensitivity Analyses  
 Type of model  
 Primary independent 
variable 
 
 Dependent variable  
 Covariates  
 
 
 
See Appendix D for Output tables 
 
1. Cohort selection (Table 1) 
a. Report the number of patients in cohort overall, and for each drug 
group  
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2. Total event rate (Table 2)  
a. Report the total number of events overall  
 
Stop here for discussion 
 
3. Baseline characteristics (Table 3) 
a. Report baseline characteristics prior to propensity matching  
b. Calculate the standardized difference between the two study groups: 1) 
Exposed: carvedilol (DCLASS= “S_BBC”) and 2) Unexposed: 
metoprolol (DCLASS= “S_BBM”)  
 
Stop here for discussion  
 
4. Primary analysis: Propensity scores  
a. Propensity scores: calculate propensity score based on all baseline 
characteristics below. Also report the probability (0 to 1) for pre- and 
post-weight 
 
(Note: The propensity score is the probability of exposure (E) conditional on the 
covariates (baseline characteristics). This score involves a logistic model that estimates 
the probability of being started on a specific anti-depressant, given these covariates. 
Thus, patients with similar calculated probabilities will be compared to each other, in an 
effort to eliminate bias.) 
 
Include the following variables in the derivation of the propensity score using a 
multivariable logistic regression model:  
 
 Sex (female* vs. male) – predictor of mortality 
 Age (in years, continuous variable) – predictor of mortality 
 Abdominal aortic aneurysm (yes vs. no*) – predictor of mortality, probably 
 Coronary artery disease (yes vs. no*) – predictor of mortality 
 Heart failure (yes vs. no*) – predictor of mortality, requirement for carvedilol 
(true confounder) 
 Peripheral vascular disease (yes vs. no*) -– predictor of mortality 
 Stroke (yes vs. no*) – predictor of mortality 
 Use of ACE inhibitors (yes vs. no*) – predictor of mortality, requirement for 
carvedilol (true confounder) 
 Use of alpha blockers (yes vs. no*) – measure of HTN, predictor of mortality 
 Use of ARBs (yes vs. no*) - predictor of mortality, requirement for carvedilol 
(true confounder) 
 Use of calcium channel blockers (yes vs. no*)  - measure of HTN, predictor of 
mortality 
 Use of diabetes drugs (yes vs. no*) – predictor of mortality 
 Use of digoxin (yes vs. no*)  - predictor of mortality, requirement for 
carvedilol (true confounder) 
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 Use of nitrates (yes vs. no*) 
 Cardiologist visit (yes vs. no*) – requirement for carvedilol 
 Coronary revascularization (yes vs. no*) 
 Echocardiogram (yes vs. no*) – requirement for carvedilol 
 Comorbidity score (continuous) – predictor of mortality 
 
b. Baselines: Report baseline characteristics after matching and 
standardized differences (Table 4)  
- Calculate the standardized difference between the two study 
groups: 1) Exposed: carvedilol (DCLASS= “S_BBC”) and 2) 
Unexposed: metoprolol (DCLASS= “S_BBM”)  
c. Events: Determine aggregate event rates for all outcomes after 
matching according to each study group: 1) Exposed: carvedilol 
(DCLASS= “S_BBC”) and 2) Unexposed: metoprolol (DCLASS= 
“S_BBM”)  (Table 5)  
 
Hard & Propensity Score Matching 
We will use greedy matching with specified caliper width of ± 0.2 x the standard 
deviation of the logit of the propensity score 
 Austin, 2010 showed that the above caliper width results in optimal estimation of 
difference in the risk 
 Since we have a specified caliper width, the difference in the logit of the 
propensity score between exposed and unexposed patients in the matched set is 
required to be less than the pre-specified maximum caliper width 
We will match without replacement 
 Since we are matching without replacement, matched unexposed patients can no 
longer serve as a candidate for being matched to another exposed patient 
 
Matching Ratio:  We will match 1 exposed patient with 2 unexposed patients on: 
 The logit of the propensity score 
 Age ± 2 years 
 Sex 
 
Stop here for discussion 
Note: If we lose >80% of carvedilol patients through matching, then will switch to 
propensity weighting 
 
d. Regression (Table 6): Using the matched cohort from above, report 
the absolute risk difference, odds ratio and 95% confidence interval by 
performing conditional logistic regression analyses for all outcomes 
using the exposed (DCLASS = “S_BBC”) and unexposed (DCLASS= 
“S_BBM”, referent) study groups (Note: since outcomes are rare we 
can approximate risk ratios from odds ratios)  
 
Stop here for discussion  
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 Additional analysis: TBD  
 
 Quality Assurance Activities  
RAE Directory of SAS 
Programs 
 
RAE Directory of Final 
Dataset(s) 
The final analytic dataset for each cohort includes all the 
data required to create the baseline tables and run all the 
models. It should include all covariates for all models 
such as patient risk factors, hospital characteristics, 
physician characteristics, exposure measures (continuous, 
categorical) and outcomes. It should include covariates 
that were considered but didn’t make the final cut. This 
would permit an analyst to easily re-run the models in the 
future. 
 
RAE README file available: ☐Yes ☐No 
Date results of quality assurance tools for final dataset shared 
with project team (where applicable): 
 
 %assign yyyy-mon-dd 
 %evolution yyyy-mon-dd 
 %dinexplore yyyy-mon-dd 
 %track / %exclude yyyy-mon-dd 
 %codebook yyyy-mon-dd 
Additional comments:  
 
Appendix A – Drug List 
CarvedilolDrugList16
0201.xlsx
 
 
Appendix B – Cohort build 
 
 
Appendix C – Outcomes 
 
 
Appendix D – Output tables 
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CarvedilolOutputTabl
es160205.xlsx
 
 
Appendix E – Baseline codes 
 
 
Appendix F – Baseline table  
 
Assume below unless stated:  
 
CIHI-DAD  
Source 
 All 
Institution types 
 Acute care (insttype = ‘AP’ or ‘AT’) 
Include suspected/questionable diagnoses? 
 No 
 
OHIP: 
Claim Type 
 NONLAB 
 
NACRS  
Source 
 Emergency Department visits 
Include planned visits 
 No 
 
Characteristic Code Set Datasets Used Other Details 
Demographics 
Age  RPDB Report as mean, 
SD, median, 25th, 
75h percentiles, 
and N (%) in 
categories (66-69, 
70-74, 75-79, 80-
84, 85-89, ≥90) 
Sex  RPDB N (%) female 
Rurality  PSTLYEAR 
Macro: %GETDEMO 
Var name: RURAL 
N (%) rural 
Socioeconomic  PSTLYEAR Report as quintiles 
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Status – 
Neighbourhood 
Income Quintile  
Macro: %GETDEMO 
Var:name: INCQUINT 
(1, 2, 3, 4, 5, or 
missing) 
 
Income quintiles 
using average 
neighbourhood 
income on index 
date as defined by 
Statistics Canada 
 
1 is lowest quintile 
(poorest) and 5 is 
highest quintile 
(richest) 
Year of index 
event (2002-
2014) 
  Report as N (%) in 
categories: 2002, 
2003, 2004, 2005, 
2006, 2007, 2008, 
2009, 2010, 2011, 
2012, 2013, 2014 
Comorbidities (5 year look back except Charlson and John Hopkins scores) 
Abdominal 
aortic aneurysm 
 CIHI DAD 
OHIP 
N (%) yes 
Arrhythmia  CIHI DAD 
NACRS 
OHIP 
N (%) yes 
Chronic liver 
disease 
 CIHI DAD 
NACRS 
N (%) yes 
Chronic lung 
disease 
 CIHI DAD 
NACRS 
OHIP 
N (%) yes 
Coronary artery 
disease (without 
angina) 
 CIHI DAD 
OHIP 
NACRS 
N (%) yes 
Heart failure  CIHI DAD 
NACRS 
N (%) yes 
Implantable 
defibrillator 
 CIHI DAD 
OHIP 
N (%) yes 
Kidney 
transplant  
 CIHI DAD 
OHIP 
N (%) yes 
Myocardial 
infarction 
 CIHI-DAD N (%) yes 
Pacemaker   CIHI DAD 
OHIP 
N (%) yes 
Peripheral 
vascular disease 
 CIHI DAD 
NACRS 
N (%) yes 
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Stroke  CIHI DAD 
NACRS 
N (%) yes 
TIA  CIHI DAD 
NACRS 
N (%) yes 
Charlson 
comorbidity 
score (2 year 
lookback)  
 CIHI DAD 
1. Identify all acute DAD 
records for patients in 2 years 
prior (do not include index 
date) 
2. Use the %charlson macro and 
collapse over IKN – read macro 
definitions 
3. Keep the ‘charl’ variable 
(weighted sum of the above 
indicators) and provide 
frequency results 
N (%):  
0 or no 
hospitalization 
1 hospitalization 
2 hospitalizations 
3+ hospitalizations 
 
And report as 
Mean, SD, 
Median, 25th & 
75th percentiles 
John Hopkins 
comorbidity 
score (2 year 
look back) 
 Use %getacg macro to create 
Johns Hopkins ACG ADG 
scores, based on ICD-9, ICD-
10-CA, OHIP codes 
Report as mean, 
SD, median, 25th 
percentile, 75th 
percentile  
 
Report as 0-4, 5-9, 
10-14, 15-19, ≥20, 
missing scores 
 
missing will be 
included in the 
category that 
contains the 
median value for 
the ACG score 
Medication use (1 year look back) 
ACE inhibitor BC_ACE ODB N (%) yes 
Amiodarone BC_AMI ODB N (%) yes 
ARB BC_ARB ODB N (%) yes 
Alpha blocker BC_AAB ODB N (%) yes 
Calcium channel 
blocker 
BC_CCB ODB N (%) yes 
Diabetes drugs BC_DBT ODB N (%) yes 
Digoxin BC_DIG ODB N (%) yes 
Nitrate BC_NIT ODB N (%) yes 
Statins BC_STA ODB N (%) yes 
Warfarin BC_WAR ODB N (%) yes 
Health services utilization (1 year lookback)  
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Cardiologist visit  OHIP N (%) yes 
 
Spec = “60” 
(Cardiology)  
 
Count only one 
claim per patient 
per day. 
Primary care 
visit 
 
 
OHIP N (%) yes 
 
Report as 0-4, 5-9, 
10-14, 15-19, 20-
24, 25-29, ≥30 
visits in the 
previous year 
 
Spec = “00” 
(Family practice 
and general 
practice)  
 
Count only one 
claim per patient 
per day. 
Carotid 
ultrasound  
 CIHI DAD 
OHIP 
N (%) yes 
Coronary 
angiogram 
 CIHI DAD 
OHIP 
N (%) yes 
Coronary 
revascularization 
 CIHI DAD 
OHIP 
N (%) yes 
Hemodialysis 
duration 
 OHIP Time from index 
date back to the 
date of 
hemodialysis 
initiation (days) 
 
Initiation of 
dialysis definition: 
1. OHIP 
feecode 
R849 (if 
multiple 
R849s 
exist, select 
the most 
recent) 
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OR (if R849 is not 
found) 
 
Earliest recorded 
chronic 
hemodialysis 
feecode (H540, 
H740, G325, 
G326, G860, 
G862, G863, 
G866) 
 
Report mean, SD, 
median, 25th & 75th 
percentile, 
minimum, 
maximum 
Echocardiogram  CIHI DAD 
OHIP 
N (%) yes 
Holter 
monitoring 
 CIHI DAD 
OHIP 
N (%) yes 
Stress testing   CIHI DAD 
OHIP 
N (%) yes 
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